1. ‫ﻣﺠﻠﻪ‬‫ﻋﻠﻮم‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22،‫ﺷﻤﺎره‬134،‫ﻣ‬‫ﺮ‬‫داد‬1394http://rjms.iums.ac.ir‫ﭘﮋوﻫﺸﯽ‬ ‫ﻣﻘﺎﻟﻪ‬
‫ﻣﻘﺪﻣﻪ‬
‫اﻧﺠﺎم‬‫ﻓﻌﺎﻟﯿﺖ‬‫ﺧﺼـﻮص‬ ‫ﺑـﻪ‬ ‫ﺷـﺪﯾﺪ‬ ‫ورزﺷـﯽ‬ ‫ﻫﺎي‬
‫ـﺖ‬‫ـ‬‫ﻓﻌﺎﻟﯿ‬‫ـﻪ‬‫ـ‬‫وزﻧ‬ ‫ـﺎ‬‫ـ‬‫ﺑ‬ ‫ـﺎوﻣﺘﯽ‬‫ـ‬‫ﻣﻘ‬ ‫ـﺎي‬‫ـ‬‫ﻫ‬‫ـﻪ‬‫ـ‬‫ﺑ‬‫ـﺖ‬‫ـ‬‫ﻋﻠ‬‫ـﺰاﯾﺶ‬‫ـ‬‫اﻓ‬
‫ﻣﮑﺎﻧﯿﮑﯽ‬ ‫ﻓﺸﺎرﻫﺎي‬-‫ﻣﺘـﺎﺑﻮﻟﯿﮑﯽ‬‫دﺳـﺘﮕﺎه‬ ‫ﺳـﺮﮐﻮب‬ ‫و‬
‫ﭘﺎﺳﺦ‬ ‫آﻏﺎز‬ ‫ﻣﻮﺟﺐ‬ ‫اﯾﻤﻨﯽ‬‫اﻟﺘﻬـﺎﺑﯽ‬ ‫آﺑﺸـﺎرﻫﺎي‬ ‫و‬ ‫ﻫـﺎ‬
‫ﻣﯽ‬ ‫ﻣﺨﺘﻠﻔﯽ‬‫ﺷﻮ‬‫ﻧ‬‫ﺪ‬)1(‫ﭘﺎﺳـﺦ‬ ‫اﯾﻦ‬ .،‫ورم‬ ‫ﺷـﺎﻣﻞ‬ ‫ﻫـﺎ‬
‫ﺗﻌﺪاد‬ ‫اﻓﺰاﯾﺶ‬ ،‫درد‬‫ﻟﮑﻮﺳﯿﺖ‬‫ﻣﺤﯿﻄـﯽ‬ ‫ﺧـﻮن‬ ‫ﻫـﺎي‬
‫)ﺑﻪ‬‫ﻧﻮﺗﺮوﻓﯿﻞ‬ ‫ﺗﺠﻤﻊ‬ ‫وﯾﮋه‬‫ﻣﻮﻧﻮﺳﯿﺖ‬ ‫و‬ ‫ﻫﺎ‬‫اﻓﺰاﯾﺶ‬ ،(‫ﻫﺎ‬
‫ﻣﯿﺎﻧﺠﯽ‬ ‫ﻣﯿﺰان‬ ‫ﺳﺮﯾﻊ‬‫ﺳﺎﯾﺘﻮﮐﯿﻦ‬ ‫و‬ ‫ﻫﺎ‬‫اﻟﺘﻬـﺎﺑﯽ‬ ‫ﻫـﺎي‬
‫ﺑﻪ‬‫دﻫﻨﺪه‬ ‫ﻧﮑﺮوز‬ ‫ﻋﺎﻣﻞ‬ ‫وﯾﮋه‬‫آﻟﻔﺎ‬ ‫ﺗﻮﻣﻮر‬ ‫ي‬)TNF-α(،
‫ﯾﮏ‬ ‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬-‫ﺑﺘﺎ‬)IL-1β(‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫و‬-‫ﺷﺶ‬
)IL-6() ‫اﺳﺖ‬2‫و‬3.(‫ﺑﻪ‬‫و‬ ‫ﻓـﺎﺗﻮروس‬ ،‫ﻣﺜـﺎل‬ ‫ﻋﻨـﻮان‬
‫ـ‬‫ـ‬‫ﺑ‬ ‫ـﺎران‬‫ـ‬‫ﻫﻤﮑ‬‫ﻪ‬‫ـﺖ‬‫ـ‬‫ﻓﻌﺎﻟﯿ‬ ‫ـﻪ‬‫ـ‬‫ﺟﻠﺴ‬ ‫ـﮏ‬‫ـ‬‫ﯾ‬ ‫ـﺎم‬‫ـ‬‫اﻧﺠ‬ ‫ـﺎل‬‫ـ‬‫دﻧﺒ‬
‫داﯾﺮه‬ ‫ﻣﻘﺎوﻣﺘﯽ‬‫ﺑﻪ‬ ‫اي‬‫ﻣﺪت‬30‫در‬ ‫دﻗﯿﻘـﻪ‬17‫ﻣـﺮد‬
‫ﺳﻄﻮح‬ ‫ﻣﯿﺰان‬ ‫ﮐﻪ‬ ‫ﮐﺮدﻧﺪ‬ ‫ﮔﺰارش‬ ‫ﺳﺎﻟﻢ‬ ‫ﺟﻮان‬IL-6
‫و‬TNF-α‫اﻓــﺰاﯾﺶ‬ ‫ﻓﻌﺎﻟﯿــﺖ‬ ‫از‬ ‫ﭘــﺲ‬ ‫ﺑﻼﻓﺎﺻــﻠﻪ‬
‫ﻣﻌﻨﯽ‬) ‫ﯾﺎﺑـﺪ‬ ‫ﻣﯽ‬ ‫داري‬4.(‫و‬ ‫ﺑـﺎرﮐﻮﯾﻼ‬ ،‫ﻫﻤﭽﻨـﯿﻦ‬
‫ﺗﺄﺛﯿﺮات‬ ‫ﺗﻌﯿﯿﻦ‬ ‫ﻫﺪف‬ ‫ﺑﺎ‬ ‫ﺗﺤﻘﯿﻘﯽ‬ ‫ﻣﺘﻌﺎﻗﺐ‬ ‫ﻫﻤﮑﺎران‬
‫ـﯿﻨﻪ‬‫ـ‬‫ﺑﯿﺸ‬ ‫ـﺮار‬‫ـ‬‫ﺗﮑ‬ ‫ـﮏ‬‫ـ‬‫ﯾ‬‫آ‬ ‫ي‬‫ـﺮ‬‫ـ‬‫ﺑ‬ ‫ـﯿﻨﻪ‬‫ـ‬‫ﺳ‬ ‫ـﺮس‬‫ـ‬‫ﭘ‬ ‫ـﻮن‬‫ـ‬‫زﻣ‬
‫ﺷﺎﺧﺺ‬‫واﮐﻨﺸﮕﺮ‬ ‫)ﭘﺮوﺗﺌﯿﻦ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬-C‫ﻋﺎﻣﻞ‬ ،
‫دﻫﻨﺪه‬ ‫ﻧﮑﺮوز‬‫در‬ (‫ﺷﺶ‬ ‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫و‬ ‫آﻟﻔﺎ‬ ‫ﺗﻮﻣﻮر‬ ‫ي‬
11) ‫ﺳﺎﻟﻢ‬ ‫آزﻣﻮدﻧﯽ‬8‫و‬ ‫ﻣﺮد‬3‫ﺟﻤـﻊ‬ ‫ﺑﺎ‬ (‫زن‬‫آوري‬
‫ﻧﻤﻮﻧﻪ‬ ‫ﻣﺘﻨﺎوب‬‫در‬ ‫ﺧﻮﻧﯽ‬ ‫ﻫﺎي‬1،24،48‫و‬ ‫ﺳـﺎﻋﺖ‬
6‫ـﺰان‬‫ـ‬‫ﻣﯿ‬ ‫ـﻪ‬‫ـ‬‫ﮐ‬ ‫ـﺪ‬‫ـ‬‫ﮐﺮدﻧ‬ ‫ـﻼم‬‫ـ‬‫اﻋ‬ ‫ـﺖ‬‫ـ‬‫ﻓﻌﺎﻟﯿ‬ ‫از‬ ‫ـﺲ‬‫ـ‬‫ﭘ‬ ‫روز‬
‫راﻣ‬‫ﯿ‬‫ﻦ‬‫اﻣ‬‫ﯿ‬‫ﺮﺳﺎﺳﺎن‬:‫داﻧﺸﯿﺎر‬،‫ﻣﺘﺨﺼﺺ‬‫ﻓﯿﺰﯾﻮﻟﻮژ‬‫ي‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮑﺪه‬‫ي‬‫ﺗﺮﺑ‬‫ﯿ‬‫ﺖ‬‫ﺑﺪﻧ‬‫ﯽ‬‫و‬‫ﻋﻠﻮم‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮕﺎه‬،‫ﺗﺒﺮﯾﺰ‬‫ﺗﺒﺮ‬‫ﯾ‬،‫ﺰ‬‫ا‬‫ﯾ‬‫ﺮان‬.amirsasan@tabrizu.ac.ir
‫ﻣ‬‫ﯿ‬‫ﺮﻣﺠ‬‫ﯿ‬‫ﺪ‬‫ﺧﺎﻟﻘ‬‫ﯽ‬‫آﻧﺒﺎردان‬:‫ﮐﺎرﺷﻨﺎس‬‫ارﺷﺪ‬،‫ﮔﺮوه‬‫ﻓﯿﺰﯾﻮﻟﻮژ‬‫ي‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮑﺪه‬‫ي‬‫ﺗﺮﺑ‬‫ﯿ‬‫ﺖ‬‫ﺑﺪﻧ‬‫ﯽ‬‫و‬‫ﻋﻠﻮم‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮕﺎه‬،‫ﺗﺒﺮﯾﺰ‬‫ﺗﺒﺮ‬‫ﯾ‬،‫ﺰ‬‫ا‬‫ﯾ‬‫ﺮان‬.Arashkhaleghi68@yahoo.com
*‫ﻋﻠ‬‫ﯽ‬‫ﺿﺮﻏﺎﻣ‬‫ﯽ‬‫ﺧﺎﻣﻨﻪ‬:‫داﻧﺸﺠﻮ‬‫ي‬‫دﮐﺘﺮ‬‫ي‬،‫ﮔﺮوه‬‫ﻓﯿﺰﯾﻮﻟﻮژ‬‫ي‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮑﺪه‬‫ي‬‫ﺗﺮﺑ‬‫ﯿ‬‫ﺖ‬‫ﺑﺪﻧ‬‫ﯽ‬‫و‬‫ﻋﻠﻮم‬‫ورزﺷ‬‫ﯽ‬،‫داﻧﺸﮕﺎه‬،‫ﺗﺒﺮﯾﺰ‬‫ﺗﺒﺮ‬‫ﯾ‬،‫ﺰ‬‫ا‬‫ﯾ‬‫ﺮان‬(‫ﻣﺴﺌﻮل‬ ‫)*ﻧﻮﯾﺴﻨﺪه‬.
ali.zarghami64@gmail.com
‫ﺗﺄﺛ‬‫ﯿ‬‫ﺮ‬‫ﺣﺎد‬‫ﺗﻤﺮ‬‫ﯾ‬‫ﻨﺎت‬‫ﻣﻘﺎوﻣﺘ‬‫ﯽ‬‫واﻣﺎﻧﺪه‬‫ﺳﺎز‬‫و‬‫ﻣﺼﺮف‬‫ﻣﻘﺎد‬‫ﯾ‬‫ﺮ‬‫ﻣﺨﺘﻠﻒ‬‫ﮐﺎﻓﺌ‬‫ﯿ‬‫ﻦ‬‫ﺑﺮ‬‫ﭘﺎﺳﺦ‬
‫ا‬‫ﯾ‬‫ﻨﺘﺮﻟﻮﮐ‬‫ﯿ‬‫ﻦ‬-6
‫ﭼﮑﯿﺪه‬
‫زﻣﯿﻨﻪ‬‫و‬‫ﻫﺪف‬:‫ﻣﺘﯿﻞ‬ ‫ﺗﺮﮐﯿﺒﺎت‬ ‫ﺣﺎد‬ ‫اﺛﺮات‬ ‫ﺑﻪ‬ ‫ﻣﺮﺑﻮط‬ ‫ﻣﺘﻨﺎﻗﺾ‬ ‫و‬ ‫ﻣﺤﺪود‬ ‫ﻧﺘﺎﯾﺞ‬ ‫ﺑﻪ‬ ‫ﺗﻮﺟﻪ‬ ‫ﺑﺎ‬‫ﭘﺎﺳﺦ‬ ‫ﺑﺮ‬ ‫ﮔﺰاﻧﺘﯿﻨﯽ‬‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﻧﺎﺷﯽ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬‫ﻣﻄﺎﻟﻌـﻪ‬ ،‫ﺑـﺪﻧﯽ‬‫ﺣﺎﺿـﺮ‬ ‫ي‬
‫ﺑﻪ‬‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﭘﺎﺳﺦ‬ ‫ﺑﺮ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﺗﺄﺛﯿﺮ‬ ‫ﺗﻌﯿﯿﻦ‬ ‫ﻣﻨﻈﻮر‬-6‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺟﻠﺴﻪ‬ ‫ﯾﮏ‬ ‫اﻧﺠﺎم‬ ‫ﻣﺘﻌﺎﻗﺐ‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬ ‫ﻣﺮدان‬ ‫ﺳﺮﻣﯽ‬‫واﻣﺎﻧـﺪه‬‫ﺳـﺎز‬
.‫ﺷﺪ‬ ‫اﻧﺠﺎم‬
‫روش‬:‫ﮐﺎر‬30‫ﺳﻦ‬ ‫)ﻣﯿﺎﻧﮕﯿﻦ‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬ ‫ﻣﺮد‬45/1±47/21‫ﭼﺮﺑﯽ‬ ‫درﺻﺪ‬ ،‫ﺳﺎل‬11/347/10‫ﺗـﻮده‬ ‫ﺷـﺎﺧﺺ‬ ‫و‬ ‫درﺻـﺪ‬‫ﺑـﺪﻧﯽ‬ ‫ي‬26/1±15/23‫ﺑـﺮ‬ ‫ﮐﯿﻠـﻮﮔﺮم‬
‫ﻧﯿﻤﻪ‬ ‫ﻃﺮح‬ ‫ﯾﮏ‬ ‫ﻗﺎﻟﺐ‬ ‫در‬ (‫ﻣﺘﺮ‬ ‫ﻣﺠﺬور‬‫ﺑﻪ‬ ‫ﮐﻮر‬ ‫دوﺳﻮﯾﻪ‬ ‫و‬ ‫ﺗﺠﺮﺑﯽ‬‫)ﺑﺎ‬ ‫ﻣﮑﻤﻞ‬ ‫ﮔﺮوه‬ ‫ﺳﻪ‬ ‫در‬ ‫ﺗﺼﺎدﻓﯽ‬ ‫ﻃﻮر‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬‫و‬ (‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﺑـﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬
‫ﺷﺒﻪ‬) ‫دارو‬6‫ﻣﯿﻠﯽ‬.‫ﺷﺪﻧﺪ‬ ‫ﺟﺎﯾﮕﺰﯾﻦ‬ (‫دﮐﺴﺘﺮوز‬ ‫ﺑﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬ ‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬‫آزﻣﻮدﻧﯽ‬‫ﻫﺎ‬45‫دﻗﯿﻘﻪ‬‫ﻣﮑﻤﻞ‬ ‫از‬ ‫ﭘﺲ‬‫دﻫﯽ‬‫ﻗﺮارداد‬ ‫ﯾﮏ‬ ‫در‬‫ﻓﻌﺎﻟﯿـﺖ‬‫ﺑـﺎ‬ ‫ﻣﻘـﺎوﻣﺘﯽ‬
‫وزﻧﻪ‬)‫ﺷﺎﻣﻞ‬7‫در‬ ‫ﺣﺮﮐﺖ‬3‫ﻧﻮﺑﺖ‬‫ﺑﺎ‬80‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮار‬ ‫ﯾﮏ‬ ‫درﺻﺪ‬‫واﻣﺎﻧﺪﮔﯽ‬ ‫ﺗﺎﺣﺪ‬‫ﺷﺮﮐﺖ‬ (‫ﻧﻤﻮدﻧﺪ‬.‫ﺷـﺎﺧﺺ‬ ‫ﺗﻐﯿﯿﺮات‬‫)اﯾﻨﺘﺮﻟـﻮﮐﯿﻦ‬ ‫اﻟﺘﻬـﺎﺑﯽ‬-6‫ﺳـﻪ‬ ‫ﻃـﯽ‬ (‫ﺳـﺮﻣﯽ‬
،‫ﭘﺎﯾﻪ‬ ‫)ﺣﺎﻟﺖ‬ ‫ﻣﺮﺣﻠﻪ‬45‫ﻣﮑﻤﻞ‬ ‫ﻣﺼﺮف‬ ‫از‬ ‫ﺑﻌﺪ‬ ‫دﻗﯿﻘﻪ‬(‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫)ﻗﺒﻞ‬‫اﻧﺪازه‬ (‫ﺗﻤﺮﯾﻨﯽ‬ ‫ﻗﺮارداد‬ ‫از‬ ‫ﭘﺲ‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬ ‫و‬‫داده‬ .‫ﺷﺪ‬ ‫ﮔﯿﺮي‬‫ﻧﺮﻣﺎل‬ ‫ﻫﺎي‬‫آزﻣـﻮن‬ ‫ﺑﺎ‬‫ﻫـﺎي‬‫ﺗﺤﻠﯿـﻞ‬
‫ﺑﻮﻧﻔﺮوﻧﯽ‬ ‫ﺗﻌﻘﯿﺒﯽ‬ ‫و‬ ‫ﻣﮑﺮر‬ ‫وارﯾﺎﻧﺲ‬‫ﻣﻌﻨﯽ‬ ‫ﺳﻄﺢ‬ ‫در‬‫داري‬05/0‫ﺷﺪ‬ ‫ﺑﺮرﺳﯽ‬.
‫ﯾ‬‫ﺎﻓﺘﻪ‬:‫ﻫﺎ‬‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫اﺳﺖ‬ ‫ﺣﺎﮐﯽ‬ ‫ﻧﺘﺎﯾﺞ‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﻣﻌﻨـﯽ‬ ‫اﻓـﺰاﯾﺶ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫ﭘﺎﯾﻪ‬ ‫ﺣﺎﻟﺖ‬ ‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﮔﺮم‬‫اﯾﻨﺘﺮﻟـﻮﮐﯿﻦ‬ ‫ﺗﻐﯿﯿـﺮات‬ ‫دار‬-6‫ﺳـﺮم‬‫ﻣـﯽ‬‫ﺷـﻮﻧﺪ‬
)05/0p≤‫ﺑﻪ‬ .(‫ﻣﻘﺎدﯾﺮ‬ ‫دو‬ ‫ﻫﺮ‬ ‫ﻣﺼﺮف‬ ،‫ﻋﻼوه‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﺷﺎﺧﺺ‬ ‫اﻓﺰاﯾﺸﯽ‬ ‫ﭘﺎﺳﺦ‬ ‫ﺗﺸﺪﯾﺪ‬ ‫ﺑﺎﻋﺚ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺑﺎ‬ ‫ﺗﻌﺎﻣﻞ‬ ‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﮔﺮم‬‫ﮔﺮوه‬ ‫ﺑﺎ‬ ‫ﻣﻘﺎﯾﺴﻪ‬ ‫در‬ ‫اﻟﺘﻬﺎﺑﯽ‬
) ‫ﺷﺪ‬ ‫داروﻧﻤﺎ‬05/0p≤.(
‫ﻧﺘﯿﺠﻪ‬‫ﮔﯿﺮي‬‫ﯾﺎﻓﺘﻪ‬ ‫اﺳﺎس‬ ‫ﺑﺮ‬ :‫ﻣﯽ‬ ،‫ﺣﺎﺿﺮ‬ ‫ﭘﮋوﻫﺶ‬ ‫ﻫﺎي‬‫ﭘـﺎﯾﯿﻦ‬ ‫ﺳـﻄﺢ‬ ‫اﻟﺘﻬـﺎب‬ ‫ﺑﺎﻋـﺚ‬ ‫ﭘﺎﯾـﻪ‬ ‫ﺣﺎﻟـﺖ‬ ‫در‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫ﮔﺮﻓﺖ‬ ‫ﻧﺘﯿﺠﻪ‬ ‫ﺗﻮان‬
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫)اﻓﺰاﯾﺶ‬-6‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﺷﺎﺧﺺ‬ ‫ﭘﺎﺳﺦ‬ ‫ﺗﻌﺪﯾﻞ‬ ‫ﺟﻬﺖ‬ ‫ﻻزم‬ ‫ﺗﻮاﻧﺎﯾﯽ‬ ‫ﻫﻤﭽﻨﯿﻦ‬ ‫و‬ ‫ﺷﺪه‬ (‫ﺳﺮﻣﯽ‬‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬ ‫ﻣﺮدان‬‫از‬ ‫ﻧﺎﺷﯽ‬‫ﻣﻘـﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺟﻠﺴﻪ‬ ‫ﯾﮏ‬ ‫اﻧﺠﺎم‬
‫واﻣﺎﻧﺪه‬.‫ﻧﺪارد‬ ‫را‬ ‫ﺳﺎز‬
‫ﮐﻠﯿﺪواژه‬‫ﻫﺎ‬‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ :-6‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﺣﺎد‬ ‫ﺗﻤﺮﯾﻨﺎت‬ ،‫ﮐﺎﻓﺌﯿﻦ‬ ،
:‫درﯾﺎﻓﺖ‬ ‫ﺗﺎرﯾﺦ‬5/11/93:‫ﭘﺬﯾﺮش‬ ‫ﺗﺎرﯾﺦ‬5/3/94

2. ‫راﻣ‬‫ﯿ‬‫ﻦ‬‫اﻣ‬‫ﯿ‬‫ﺮﺳﺎﺳﺎن‬‫ﻫﻤﮑﺎر‬ ‫و‬‫ان‬
‫ﻣﺠﻠﻪ‬‫ﻋﻠﻮم‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394http://rjms.iums.ac.ir
50
‫ﺷﺎﺧﺺ‬ ‫ﺗﻤﺎﻣﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬‫اﻓـﺰاﯾ‬ ‫ﻫﺎ‬‫ﻣﻌﻨـﯽ‬ ‫ﺶ‬‫در‬ ‫داري‬
) ‫داﺷﺖ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﻗﺒﻞ‬ ‫ﺑﺎ‬ ‫ﻣﻘﺎﯾﺴﻪ‬5‫ﺣﺎﻟﯽ‬ ‫در‬ ‫اﯾﻦ‬ .(
‫ﭘﺰﺷـﮑﯽ‬ ‫ﻣﺤﻘﻘﯿﻦ‬ ‫ﺑﺮﺧﯽ‬ ‫اﺧﯿﺮ‬ ‫ﺳﺎﻟﯿﺎن‬ ‫در‬ ‫ﮐﻪ‬ ‫اﺳﺖ‬
‫ﮐﺮده‬ ‫ﻋﻨﻮان‬ ‫ورزﺷﯽ‬‫ﮐﻪ‬ ‫اﻧﺪ‬‫درﻣـﺎن‬ ‫از‬ ‫اﺳﺘﻔﺎده‬ ‫ﺑﺎ‬‫ﻫـﺎي‬
‫)ﻣﮑﻤﻞ‬ ‫ﺧﻮارﮐﯽ‬ ‫و‬ ‫داروﯾﯽ‬‫ﻗﺎﺑـﻞ‬ ‫ﻣﯿـﺰان‬ ‫ﺑﻪ‬ (‫ﻏﺬاﯾﯽ‬ ‫ﻫﺎي‬
‫ﻣﯽ‬ ‫ﺗﻮﺟﻬﯽ‬‫ﮐﺮد‬ ‫ﺟﻠﻮﮔﯿﺮي‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﺗﻈﺎﻫﺮات‬ ‫ﺑﺮوز‬ ‫از‬ ‫ﺗﻮان‬
)6‫اﯾ‬ ‫در‬ .(‫ﻣﮑﻤـﻞ‬ ‫ﺑﺨـﺶ‬ ‫در‬ ‫ﻣﺘﺨﺼﺼﯿﻦ‬ ،‫راﺳﺘﺎ‬ ‫ﻦ‬‫ﻫـﺎي‬
‫ﻏﺬاﯾﯽ‬‫ﻣﺘﯿـﻞ‬ ‫ﺗﺮﮐﯿﺒﺎت‬ ‫ﻣﺼﺮف‬‫ﺟﻤﻠـﻪ‬ ‫از‬ ‫ﮔﺰاﻧﺘﯿﻨـﯽ‬
‫ﺑﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬‫ﻋﻨﻮان‬‫ﻣﺘﯿﻞ‬ ‫ﭘﻮرﯾﻨﯽ‬ ‫آﻟﮑﺎﻟﻮﺋﯿﺪ‬ ‫ﯾﮏ‬‫ﻣﺸﺘﻖ‬ ‫دار‬
‫ﺧﺎﻧﻮاده‬ ‫از‬ ‫ﺷﺪه‬‫ﻣﺘﯿﻞ‬ ‫ي‬‫ﮔﺰاﻧﺘﯿﻦ‬‫ﺷـﯿﻤﯿﺎﯾﯽ‬ ‫ﻓﺮﻣﻮل‬ ‫)ﺑﺎ‬ ‫ﻫﺎ‬
C8H10N4O2(‫و‬ ‫ﺿــﺪاﻟﺘﻬﺎﺑﯽ‬ ‫اﺛــﺮات‬ ‫داراي‬ ‫ﮐــﻪ‬ ‫را‬
‫ﮐﺮده‬ ‫ﻣﻌﺮﻓﯽ‬ ،‫اﺳﺖ‬ ‫ﺿﺪاﮐﺴﯿﺪاﻧﯽ‬) ‫اﻧﺪ‬7‫و‬8.(‫ﻧﺘـﺎﯾﺞ‬
‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫اﺳﺖ‬ ‫ﺣﺎﮐﯽ‬ ‫ﻣﻮﺟﻮد‬ ‫ﺗﺤﻘﯿﻘﺎت‬ ‫از‬ ‫ﺑﺮﺧﯽ‬
‫ﻓﻌﺎﻟﯿـﺖ‬ ‫از‬ ‫ﺟﻠـﻮﮔﯿﺮي‬ ‫ﻃﺮﯾﻖ‬ ‫از‬ ‫ﮐﺎﻓﺌﯿﻨﯽ‬ ‫ﺗﺮﮐﯿﺒﺎت‬
‫آﻧﺰﯾﻢ‬‫ﭼﺮﺧـﻪ‬ ‫ﻫﺎي‬‫ﻓﺴـﻔﻮدي‬ ‫ﻧﻮﮐﻠﺌﻮﺗﯿـﺪ‬ ‫ي‬‫اﺳـﺘﺮاز‬
)PDE()8‫ﺣﻠﻘﻮي‬ ‫ﻣﻮﻧﻮﻓﺴﻔﺎت‬ ‫آدﻧﻮزﯾﻦ‬ ‫اﻓﺰاﯾﺶ‬ ،(
)cAMP()9‫ﮔﯿﺮﻧﺪه‬ ‫ﺑﺎ‬ ‫ﻣﺨﺎﻟﻔﺖ‬ ،(‫ﻫﺎي‬،‫آدﻧـﻮزﯾﻨﯽ‬
‫ﭘﺎك‬‫ﺑﻨﯿﺎن‬ ‫ﺳﺎزي‬‫ﻋﻮ‬ ‫ژن‬ ‫ﺑﯿﺎن‬ ‫ﺗﻌﺪﯾﻞ‬ ‫و‬ ‫آزاد‬ ‫ﻫﺎي‬‫اﻣﻞ‬
)‫اﻟﺘﻬﺎﺑﯽ‬NF-KB‫و‬TNF-α‫ﻣﯽ‬ (‫ﻓﺸﺎر‬ ‫ﺑﺮوز‬ ‫از‬ ‫ﺗﻮاﻧﺪ‬
‫ﭘﺎﺳﺦ‬ ‫و‬ ‫ﻣﺘﺎﺑﻮﻟﯿﮑﯽ‬) ‫ﺑﮑﺎﻫﺪ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬10‫و‬11.(
‫ـﯽ‬‫ـ‬‫ﻣﺘﻨﺎﻗﻀ‬ ‫و‬ ‫ـﺪود‬‫ـ‬‫ﻣﺤ‬ ‫ـﺎت‬‫ـ‬‫ﻣﻄﺎﻟﻌ‬ ،‫ـﺎل‬‫ـ‬‫ﺣ‬ ‫ـﻦ‬‫ـ‬‫اﯾ‬ ‫ـﺎ‬‫ـ‬‫ﺑ‬
‫درﺑﺎره‬‫ﻣﺘﺎﺑﻮﻟﯿـﺖ‬ ‫و‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﺗﺄﺛﯿﺮات‬ ‫ي‬‫ﺑـﺮ‬ ‫ﻫـﺎﯾﺶ‬
‫ﺷﺎﺧﺺ‬ ‫ﭘﺎﺳﺦ‬‫ﻫﺎي‬‫ﺑـﻪ‬ .‫دارد‬ ‫وﺟـﻮد‬ ‫اﻟﺘﻬﺎﺑﯽ‬‫ﻋﻨـﻮان‬
‫ﻣ‬ ‫ﺗﺰرﯾـﻖ‬ ‫ﺑﺮرﺳﯽ‬ ‫ﺑﺎ‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫دراي‬ ،‫ﻣﺜﺎل‬‫ﻘـﺎدﯾﺮ‬
) ‫ﮐــﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠــﻒ‬5/0،5‫و‬50‫در‬ ‫ﻣﯿﮑﺮوﮔــﺮم‬
‫ﻣﯿﻠﯽ‬‫ﺷﺪه‬ ‫ﺟﺪا‬ ‫ﺑﺎﻓﺖ‬ ‫ﺑﺮ‬ (‫ﻟﯿﺘﺮ‬‫زﻧـﺎن‬ ‫ﻫﭙﺎﺗﻮﺳـﯿﺘﯽ‬ ‫ي‬
‫ـﺎﻓﺌﯿﻦ‬‫ـ‬‫ﮐ‬ ‫ـﺘﺮ‬‫ـ‬‫ﺑﯿﺸ‬ ‫ـﺎدﯾﺮ‬‫ـ‬‫ﻣﻘ‬ ‫ـﺎ‬‫ـ‬‫ﺗﻨﻬ‬ ‫ـﻪ‬‫ـ‬‫ﮐ‬ ‫ـﺪ‬‫ـ‬‫ﻧﻤﻮدﻧ‬ ‫ـﺎن‬‫ـ‬‫ﺑﯿ‬
‫ﺑﻪ‬ ‫ﺗﻮاﻧﺴﺖ‬‫ﻣﻌﻨﯽ‬ ‫ﻃﻮر‬‫ﺗﻌﺪﯾﻞ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫داري‬TNF-
α‫و‬IL-6) ‫ﮔﺮدد‬11‫ﻣﻄﺎﻟﻌـﺎت‬ ‫ﻧﺘـﺎﯾﺞ‬ ،‫ﻣﻘﺎﺑﻞ‬ ‫در‬ .(
‫ﺳـﺎل‬ ‫در‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫ﻣﺎﭼﺎدو‬2010‫آن‬ ‫از‬ ‫ﺣـﺎﮐﯽ‬
‫ا‬) ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫ﺳﺖ‬5/4
‫و‬5/5‫ﻣﯿﻠﯽ‬‫ﻫﯿﭻ‬ (‫ﺑﺪن‬ ‫وزن‬ ‫در‬ ‫ﮔﺮم‬‫ﺑﺮ‬ ‫ﺗﺄﺛﯿﺮي‬ ‫ﮔﻮﻧﻪ‬
‫ـﺎﺧﺺ‬‫ـ‬‫ﺷ‬ ‫ﮐـﺎﻫﺶ‬‫ـﺐ‬‫ـ‬‫ﻣﺘﻌﺎﻗ‬ ‫ـﻼﻧﯽ‬‫ـ‬‫ﻋﻀ‬ ‫اﻟﺘﻬـﺎب‬ ‫ـﺎي‬‫ـ‬‫ﻫ‬
‫ﻓﻌﺎﻟﯿﺖ‬) ‫ﻧﺪارﻧﺪ‬ ‫ورزﺷﯽ‬ ‫ﻫﺎي‬12‫ﯾﺎﻓﺘﻪ‬ ‫ﺣﺘﯽ‬ ‫(؛‬‫ﻫـﺎي‬
‫دﻫﻨـﺪه‬ ‫ﻧﺸـﺎن‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫ﺗﻮﻟﺮ‬ ‫ﭘﮋوﻫﺶ‬‫ﺗﺸـﺪﯾﺪ‬ ‫ي‬
‫ﺷﺎﺧﺺ‬ ‫ﭘﺎﺳﺦ‬‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﻣﺎﻧﻨﺪ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬-‫ﺷﺶ‬
‫ﻣﺘﻌﺎ‬ ‫ده‬ ‫و‬‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﻗﺐ‬6‫ﻣﯿﻠﯽ‬‫در‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﮔﺮم‬
) ‫اﺳﺖ‬ ‫ورزﺷﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺑﺎ‬ ‫ﺗﻌﺎﻣﻞ‬13‫اﯾـﻦ‬ ‫از‬ .(‫ﺑـﺎ‬ ،‫رو‬
‫ﻫـﺪف‬ ‫ﺑـﺎ‬ ‫ﺣﺎﺿـﺮ‬ ‫ﺗﺤﻘﯿﻖ‬ ،‫ﻣﺘﻨﺎﻗﺾ‬ ‫ﻧﺘﺎﯾﺞ‬ ‫ﺑﻪ‬ ‫ﺗﻮﺟﻪ‬
‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﺗﺄﺛﯿﺮ‬ ‫ﺗﻌﯿﯿﻦ‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﮔﺮم‬
‫ﭘﺎﺳﺦ‬ ‫ﺑﺮ‬ ‫ﺑﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬ ‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬‫ﺷﺎﺧﺺ‬
) ‫اﻟﺘﻬــﺎﺑﯽ‬IL-6‫واﻟﯿﺒﺎﻟﯿﺴــﺖ‬ ‫ﻣــﺮدان‬ ‫در‬ (‫ﺳــﺮم‬
‫اﻧﺠ‬ ‫ﻣﺘﻌﺎﻗﺐ‬‫ﺑﺎوزﻧـﻪ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺟﻠﺴﻪ‬ ‫ﯾﮏ‬ ‫ﺎم‬
)‫ﺑﺎ‬‫ﺷـﺪت‬80‫ﺑﯿﺸـﯿﻨﻪ‬ ‫ﺗﮑـﺮار‬ ‫ﯾـﮏ‬ ‫درﺻـﺪ‬‫ﺗﺎﺣـﺪ‬
.‫ﺷﺪ‬ ‫اﻧﺠﺎم‬ (‫واﻣﺎﻧﺪﮔﯽ‬
‫روش‬‫ﮐﺎر‬
‫ﻃﺮح‬ ‫ﻗﺎﻟﺐ‬ ‫در‬ ،‫ﺣﺎﺿﺮ‬ ‫ﺗﺤﻘﯿﻖ‬‫ﻫـﺎي‬‫ﺳـﻪ‬ ‫ﺗﺠﺮﺑـﯽ‬
‫دو‬ (‫ﮐﻨﺘﺮل‬ ‫و‬ ‫ﺗﺠﺮﺑﯽ‬ ‫ﮔﺮوه‬ ‫)دو‬ ‫ﮔﺮوﻫﯽ‬‫ﺳﻮﯾﻪ‬‫ﮐـﻮر‬
)Double blind‫اﻧــﺪازه‬ ‫ﺑــﺎ‬ (‫ﮔﯿــﺮي‬‫ﻣﮑــﺮر‬ ‫ﻫــﺎي‬
‫)ﺳﻪ‬‫ﻣﺮﺣﻠﻪ‬‫ﺑﯿﻦ‬ ‫از‬ ،‫ﻣﻨﻈﻮر‬ ‫اﯾﻦ‬ ‫ﺑﺮاي‬ .‫ﺷﺪ‬ ‫اﻧﺠﺎم‬ (‫اي‬
45‫ﺷـﺮﮐﺖ‬ ‫داوﻃﻠـﺐ‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬‫اﯾـﻦ‬ ‫در‬ ‫ﮐﻨﻨـﺪه‬
،‫ﭘﮋوﻫﺶ‬30‫ﺑﻪ‬ ‫ﺗﻮﺟﻪ‬ ‫ﺑﺎ‬ ‫ﻧﺨﺒﻪ‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬ ‫ﻣﺮد‬ ‫ﻧﻔﺮ‬
‫ورود‬ ‫ﻣﻌﯿﺎرﻫــﺎي‬)‫داﻣﻨــﻪ‬‫ي‬‫ﺳــﻨﯽ‬25-20،‫ﺳــﺎل‬
‫ﭼﺮﺑﯽ‬ ‫درﺻﺪ‬) ‫ﺑـﺪن‬%BF(15-10%‫ﺑـﺎﻻي‬ ‫ﻗـﺪ‬ ،
180‫ﺳﺎﻧﺘﯽ‬‫از‬ ‫ﮐﻤﺘـﺮ‬ ‫ﻣﺼـﺮﻓﯽ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﯿﺰان‬ ،‫ﻣﺘﺮ‬
100‫ﻣﯿﻠﯽ‬‫ﮔﺮم‬‫ﺑـﺎﻻي‬ ‫ﭘـﺮش‬ ‫ارﺗﻔـﺎع‬ ‫و‬ ‫روز‬ ‫در‬45
‫ـﺎﻧﺘﯽ‬‫ـ‬‫ﺳ‬‫)ﺳــﺎﺑﻘﻪ‬ ‫ورود‬ ‫ﻋــﺪم‬ ‫ﻣﻌﯿﺎرﻫــﺎي‬ ‫و‬ (‫ﻣﺘــﺮ‬‫ي‬
‫دﯾﺪﮔﯽ‬ ‫آﺳﯿﺐ‬ ‫و‬ ‫ﺑﯿﻤﺎري‬‫ﻣﭻ‬ ‫در‬ ‫وﯾﮋه‬ ‫ﺑﻪ‬ ‫ﻗﺒﻠﯽ‬ ‫ﻫﺎي‬
‫ﺧـﻮن‬ ‫ﻓﺸـﺎر‬ ،‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺑﻪ‬ ‫ﺣﺴﺎﺳﯿﺖ‬ ،‫زاﻧﻮ‬ ‫و‬ ‫ﮐﻤﺮ‬ ،‫ﭘﺎ‬
‫ﺑﯿﻤﺎري‬ ،‫ﺑﺎﻻ‬‫ﻗﻠﺒﯽ‬ ‫ﻫﺎي‬-‫ﻧـﻮع‬ ‫ﻫـﺮ‬ ‫ﻣﺼﺮف‬ ‫و‬ ‫ﻋﺮوﻗﯽ‬
‫آﻧﺘﯽ‬ ‫ﻣﮑﻤﻞ‬‫در‬ ‫اﮐﺴﯿﺪاﻧﯽ‬6‫ﺗﻮﺳـﻂ‬ ‫ﮐـﻪ‬ ‫اﺧﯿـﺮ‬ ‫ﻣﺎه‬
‫ﮔﺮد‬ ‫ﺛﺒـﺖ‬ ‫ﻧﺎﻣـﻪ‬ ‫ﭘﺮﺳﺶ‬.‫ﺷـﺪﻧﺪ‬ ‫اﻧﺘﺨـﺎب‬ (‫ﯾـﺪ‬‫اﯾـﻦ‬
‫ﺗﻮﺳــﻂ‬ ‫ﭘــﮋوﻫﺶ‬‫ﮐﻤﯿﺘــﻪ‬‫ﭘــﮋوﻫﺶ‬ ‫در‬ ‫اﺧــﻼق‬ ‫ي‬
‫ﭘﺰﺷـﮑﯽ‬ ‫ﻋﻠـﻮم‬ ‫داﻧﺸﮕﺎه‬‫ﺗﺒﺮﯾـﺰ‬‫ﺗﺄﯾﯿـﺪ‬‫ﻣﺮﮐـﺰ‬ ‫در‬ ‫و‬
:‫ﺛﺒـﺖ‬ ‫)ﮐـﺪ‬ ‫ﮔﺮدﯾـﺪ‬ ‫ﺛﺒـﺖ‬ ‫اﯾﺮان‬ ‫ﺑﺎﻟﯿﻨﯽ‬ ‫ﮐﺎرآزﻣﺎﯾﯽ‬
IRCT201112244663N7.(
‫ﻫﻤﻪ‬ ،‫اﺑﺘﺪا‬ ‫در‬‫ﺟﻠﺴﻪ‬ ‫در‬ ‫ﺣﻀﻮر‬ ‫ﺑﺎ‬ ‫داوﻃﻠﺒﯿﻦ‬ ‫ي‬‫ي‬
‫روش‬ ‫و‬ ‫اﻫﺪاف‬ ‫ﮐﺎﻣﻞ‬ ‫ﺷﺮح‬ ‫از‬ ‫ﭘﺲ‬ ‫و‬ ‫ﻫﻤﺎﻫﻨﮕﯽ‬‫ﻫﺎي‬
‫اﻧﺪازه‬،‫ﮔﯿﺮي‬‫ﺗﮑﻤﯿﻞ‬‫آﮔﺎﻫﺎﻧﻪ‬ ‫رﺿﺎﯾﺖ‬ ‫ﻓﺮم‬‫و‬‫ﭘﺮﺳﺶ‬
‫ﻧﺎﻣـﻪ‬‫ـﺎ‬‫ـ‬‫ﻫ‬‫ﺳـﻼﻣﺘﯽ‬ ‫ي‬‫ـﺪ‬‫ـ‬‫ﯾﺎدآﻣ‬ ،24‫ﺳـﺎﻋﺘﻪ‬‫ـﻢ‬‫ـ‬‫رژﯾ‬ ‫ي‬
) ‫ـﺮﻓﯽ‬‫ـ‬‫ﻣﺼ‬ ‫ـﺎﻓﺌﯿﻦ‬‫ـ‬‫ﮐ‬ ‫ـﺰان‬‫ـ‬‫ﻣﯿ‬ ‫و‬ ‫ـﺬاﯾﯽ‬‫ـ‬‫ﻏ‬14‫ـﻮرد‬‫ـ‬‫ﻣ‬ ،(
‫ﺑــﻪ‬ .‫ﮔﺮﻓﺘﻨــﺪ‬ ‫ﻗــﺮار‬ ‫ﭘﺰﺷــﮑﯽ‬ ‫ﻣﻌﺎﯾﻨــﺎت‬‫ﻣﻨﻈــﻮر‬
‫ﻫﻤﮕﻦ‬‫ﮔﺮوه‬ ‫ﺳﺎزي‬‫ﯾـﮏ‬ ،‫ﻣﻄﺎﻟﻌـﻪ‬ ‫ﻣﻮرد‬ ‫ﻫﺎي‬‫ﻫﻔﺘـﻪ‬
‫ﺗﺤﻘﯿﻖ‬ ‫ﺷﺮوع‬ ‫از‬ ‫ﻗﺒﻞ‬‫ﻣﺮﺣﻠـﻪ‬ ‫اوﻟـﯿﻦ‬ ‫از‬ ‫ﭘـﯿﺶ‬ ‫و‬‫ي‬
‫وﯾﮋﮔﯽ‬ ‫از‬ ‫ﺑﺮﺧﯽ‬ ،‫ﺧﻮﻧﮕﯿﺮي‬‫ﻓﺮ‬ ‫ﻫﺎي‬‫اﻧﺪازه‬ ‫دي‬‫ﮔﯿﺮي‬
.‫ـﺪ‬‫ـ‬‫ﺷ‬‫ـﻮدﻧﯽ‬‫ـ‬‫آزﻣ‬ ‫ـﭙﺲ‬‫ـ‬‫ﺳ‬‫ـﺎس‬‫ـ‬‫ﺑﺮاﺳ‬ ‫ـﺐ‬‫ـ‬‫داوﻃﻠ‬ ‫ـﺎي‬‫ـ‬‫ﻫ‬
‫ﺷﺎﺧﺺ‬‫ﺗـﻮده‬ ،‫ﺳﻦ‬ ،‫وزن‬ ،‫ﻗﺪ‬ ‫ﻫﺎي‬‫درﺻـﺪ‬ ،‫ﺑـﺪن‬ ‫ي‬
‫ـﯿﻨﻪ‬‫ـ‬‫ﺑﯿﺸـ‬ ‫ـﺮار‬‫ـ‬‫ﺗﮑـ‬ ‫ـﮏ‬‫ـ‬‫ﯾـ‬ ‫ـﺪرت‬‫ـ‬‫ﻗـ‬ ،‫ـﯽ‬‫ـ‬‫ﭼﺮﺑـ‬)One-
Repetition Maximum(‫ـﺎﻓﺌﯿﻦ‬‫ـ‬‫ﮐـ‬ ‫ـﺰان‬‫ـ‬‫ﻣﯿـ‬ ‫و‬

3. ‫ﺗﺄﺛ‬‫ﯿ‬‫ﺮ‬‫ﺣﺎد‬‫ﺗﻤﺮ‬‫ﯾ‬‫ﻨﺎت‬‫ﻣﻘﺎوﻣﺘ‬‫ﯽ‬‫واﻣﺎﻧﺪه‬‫ﺳﺎز‬‫و‬‫ﻣﺼﺮف‬‫ﻣﻘﺎد‬‫ﯾ‬‫ﺮ‬‫ﻣﺨﺘﻠﻒ‬‫ﮐﺎﻓﺌ‬‫ﯿ‬‫ﻦ‬‫ﺑﺮ‬‫ﭘﺎﺳﺦ‬‫ا‬‫ﯾ‬‫ﻨﺘﺮﻟﻮﮐ‬‫ﯿ‬‫ﻦ‬-6
http://rjms.iums.ac.ir‫ﻋﻠﻮم‬ ‫ﻣﺠﻠﻪ‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394
51
‫ﺑﻪ‬ ‫ﻣﺼﺮﻓﯽ‬‫ﻫﻤﮕـﻦ‬ ‫ﮔـﺮوه‬ ‫ﺳﻪ‬ ‫در‬ ‫ﺗﺼﺎدﻓﯽ‬ ‫ﻃﻮر‬10
‫ﻧﻔﺮي‬‫ﮔﺮوه‬ ‫)دو‬‫درﯾﺎﻓﺖ‬‫ﮐﻨﻨﺪه‬‫ﺣﺎد‬ ‫ي‬‫ﻣﮑﻤﻞ‬6‫و‬9
‫ﻣﯿﻠﯽ‬‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺑﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬ ‫ﻫﺮ‬
‫ﺷﺒﻪ‬ ‫و‬‫دارو‬(‫ﻣﮑﻤﻞ‬ ‫ﮔﺮوه‬ ‫ﻣﺸﺎﺑﻪ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺑﺎ‬ ‫دﮐﺴﺘﺮوز‬
.‫ﺷﺪﻧﺪ‬ ‫ﺟﺎﯾﮕﺰﯾﻦ‬‫آزﻣﻮدﻧﯽ‬ ‫از‬‫ﮐـﻪ‬ ‫ﺷـﺪ‬ ‫ﺧﻮاﺳـﺘﻪ‬ ‫ﻫـﺎ‬
‫دوره‬ ‫ﻃﯽ‬) ‫ﺗﺤﻘﯿـﻖ‬ ‫ي‬48‫ﺷـﺮوع‬ ‫از‬ ‫ﻗﺒـﻞ‬ ‫ﺳـﺎﻋﺖ‬
(‫ﺗﻤﺮﯾﻨـﯽ‬ ‫ﻗﺮارداد‬ ‫از‬ ‫ﭘﺲ‬ ‫روز‬ ‫ﯾﮏ‬ ‫ﺗﺎ‬ ‫ﻣﮑﻤﻞ‬ ‫ﻣﺼﺮف‬
‫ﻓﻌﺎﻟﯿﺖ‬ ‫اﻧﺠﺎم‬ ‫از‬‫ﻣﺼـﺮف‬ ‫و‬ ‫ﺳـﻨﮕﯿﻦ‬ ‫ورزﺷـﯽ‬ ‫ﻫـﺎي‬
‫ـﺮ‬‫ـ‬‫ﻫـ‬‫ـﺪ‬‫ـ‬‫ﺿـ‬ ‫ـﻞ‬‫ـ‬‫ﻣﮑﻤـ‬ ‫و‬ ‫دارو‬ ‫ـﻪ‬‫ـ‬‫ﮔﻮﻧـ‬‫ﻣﺎﻧﻨـــﺪ‬ ‫اﻟﺘﻬﺎﺑﯽ‬
‫ﻣﺘﯿﻞ‬‫ﮔﺰاﻧﺘﯿﻦ‬‫ﺧﻮدداري‬ ...‫و‬ ‫زﻧﺠﺒﯿﻞ‬ ،‫اﯾﺒﻮﭘﺮوﻓﻦ‬ ،‫ﻫﺎ‬
.‫ﮐﻨﻨﺪ‬‫ﻧﻤﻮﻧﻪ‬‫)ﻣﺮﺣﻠـﻪ‬ ‫ﻣﺮﺣﻠـﻪ‬ ‫ﺳـﻪ‬ ‫در‬ ‫ﺧﻮﻧﯽ‬ ‫ﻫﺎي‬‫ي‬
‫ﺷـﺒﻪ‬ ‫و‬ ‫ﻣﮑﻤـﻞ‬ ‫ﻣﺼـﺮف‬ ‫از‬ ‫ﻗﺒﻞ‬ :‫اول‬‫ﻣﺮﺣﻠـﻪ‬ ‫دارو؛‬‫ي‬
:‫دوم‬45‫ﺷـﺒﻪ‬ ‫و‬ ‫ﻣﮑﻤﻞ‬ ‫ﻣﺼﺮف‬ ‫از‬ ‫ﭘﺲ‬ ‫دﻗﯿﻘﻪ‬‫و‬ ‫دارو‬
15‫و‬ ‫ﺗﻤﺮﯾﻨــﯽ؛‬ ‫ﻗــﺮارداد‬ ‫ﺷــﺮوع‬ ‫از‬ ‫ﻗﺒــﻞ‬ ‫دﻗﯿﻘــﻪ‬
‫ﻣﺮﺣﻠﻪ‬‫ا‬ ‫ﭘـﺲ‬ ‫ﺑﻼﻓﺎﺻـﻠﻪ‬ :‫ﺳـﻮم‬ ‫ي‬‫ﻗـﺮارداد‬ ‫اﺟـﺮاي‬ ‫ز‬
(‫ﺗﻤﺮﯾﻨﯽ‬‫ﺑﻪ‬ .‫ﺷﺪ‬ ‫ﺗﻬﯿﻪ‬‫روزاﻧـﻪ‬ ‫ﻏـﺬاﯾﯽ‬ ‫رژﯾﻢ‬ ‫ﻋﻼوه‬‫ي‬
‫ﻧﺎﻣﻪ‬ ‫ﭘﺮﺳﺶ‬ ‫از‬ ‫اﺳﺘﻔﺎده‬ ‫ﺑﺎ‬ ‫اﻓﺮاد‬‫ﺗﻐﺬﯾـﻪ‬ ‫ﯾﺎدآﻣﺪ‬ ‫ي‬‫اي‬
24‫و‬ ‫ﮐـﺎﻟﺮي‬ ‫درﯾﺎﻓﺖ‬ ‫ﻣﯿﺰان‬ ‫ﺑﺮرﺳﯽ‬ ‫ﺟﻬﺖ‬ ‫ﺳﺎﻋﺘﻪ‬
‫ﻣﻐﺬي‬ ‫درﺷﺖ‬ ‫از‬ ‫درﯾﺎﻓﺘﯽ‬ ‫اﻧﺮژي‬ ‫درﺻﺪ‬‫اﺳﺎس‬ ‫ﺑﺮ‬ ‫ﻫﺎ‬
‫ﺗﻐﺬﯾــــﻪ‬ ‫اﻓــــﺰار‬ ‫ـﺮم‬‫ـ‬‫ﻧــ‬ ‫اﻃﻼﻋــــﺎﺗﯽ‬ ‫ـﮏ‬‫ـ‬‫ﺑﺎﻧــ‬‫اي‬
)Nutritionalist IV‫ﺗﺤ‬ ‫و‬ ‫ـﻪ‬‫ـ‬‫ﺗﺠﺰﯾـ‬ (.‫ـﺪ‬‫ـ‬‫ﺷـ‬ ‫ـﻞ‬‫ـ‬‫ﻠﯿـ‬
‫ـﺪه‬‫ـ‬‫وﻋ‬ ‫ـﺮﯾﻦ‬‫ـ‬‫آﺧ‬ ،‫ـﯿﻦ‬‫ـ‬‫ﻫﻤﭽﻨ‬‫ـﻮدﻧﯽ‬‫ـ‬‫آزﻣ‬ ‫ـﺬاﯾﯽ‬‫ـ‬‫ﻏ‬ ‫ي‬‫ـﺎ‬‫ـ‬‫ﻫ‬
‫)ﺻﺒﺤﺎﻧﻪ‬‫ﺷﺎﻣﻞ؛‬150،‫ﻟـﻮاش‬ ‫ﻧـﺎن‬ ‫ﮔﺮم‬40‫ﮔـﺮم‬
‫ﺷـﯿﺮ‬ ‫ﻟﯿـﻮان‬ ‫ﯾﮏ‬ ‫و‬ ‫ﺗﺒﺮﯾﺰ‬ ‫ﭘﻨﯿﺮ‬2‫ﺑـﻪ‬ ‫ﮐـﻪ‬ ‫ﭼﺮﺑـﯽ‬ %
‫ﺗﺮﺗﯿــﺐ‬61،‫ﮐﺮﺑﻮﻫﯿــﺪرات‬ %23‫و‬ ‫ﭼﺮﺑــﯽ‬ %16%
‫ﺑـﺎ‬ ‫ﺑﺮاﺑـﺮ‬ ً‫ﺎ‬‫ﺗﻘﺮﯾﺒـ‬ ‫اﻧﺮژي‬ ‫ﺣﺎوي‬ ‫ﮐﻞ‬ ‫در‬ ‫ﮐﻪ‬ ‫ﭘﺮوﺗﺌﯿﻦ‬
6/552.‫ﺑﻮد‬ ‫ﻣﺸﺎﺑﻪ‬ (‫ﮐﯿﻠﻮﮐﺎﻟﺮي‬
‫اﻧﺪازه‬‫ﯾﮏ‬ ‫ﮔﯿﺮي‬)‫ﺑﯿﺸﯿﻨﻪ‬‫ﺗﮑﺮار‬1- RM(:‫روش‬
‫ﻣﺤﺎﺳﺒﻪ‬‫ﻣﻌﺎدﻟـﻪ‬ ‫ﻣﺮداﻧﺘﻮﺳـﻂ‬ ‫ﺑﯿﺸـﯿﻨﻪ‬ ‫ﻗﺪرت‬ ‫ي‬‫ي‬
) ‫ـﺪ‬‫ـ‬‫ﺷ‬ ‫ـﯿﻦ‬‫ـ‬‫ﺗﻌﯿ‬ ‫ـﮑﯽ‬‫ـ‬‫ﺑﺮزﺳ‬15(.‫ـﺮاي‬‫ـ‬‫ﺑ‬ ‫ـﻪ‬‫ـ‬‫ﻣﻌﺎدﻟ‬ ‫ـﻦ‬‫ـ‬‫اﯾ‬
‫از‬ ‫)ﮐﻤﺘﺮ‬ ‫زﯾﺮﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮارﻫﺎي‬10‫اﺳﺘﻔﺎده‬ (‫ﺗﮑﺮار‬
‫ﻣﯽ‬‫ﺟﺎﺑﻪ‬ ‫ﺷﺨﺺ‬ ،‫آزﻣﻮن‬ ‫اﯾﻦ‬ ‫از‬ ‫اﺳﺘﻔﺎده‬ ‫ﺑﺮاي‬ .‫ﺷﻮد‬
‫ﺗﮑـﺮار‬ ‫واﻣﺎﻧـﺪﮔﯽ‬ ‫ﺣﺪ‬ ‫ﺗﺎ‬ ‫را‬ ‫ﺑﯿﺸﯿﻨﻪ‬ ‫وزﻧﻪ‬ ‫ﯾﮏ‬ ‫ﺟﺎﯾﯽ‬
‫ﻣﯽ‬‫ﺗﻮ‬ ‫ﺑﺎ‬ ‫ﺳﭙﺲ‬ ‫و‬ ‫ﮐﻨﺪ‬‫ﻣﻌﺎدﻟـﻪ‬ ‫ﺑـﻪ‬ ‫ﺟﻪ‬،‫زﯾـﺮ‬ ‫ي‬‫ﯾـﮏ‬
‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮار‬‫ﻣﯽ‬ ‫ﺑﺮآورد‬ ‫ﺣﺮﮐﺖ‬ ‫آن‬ ‫ﺑﺮاي‬ ‫او‬:‫ﺷﻮد‬
‫ﺗﮑﺮار‬ )]×0278/0(-0278/1[÷‫ﺟﺎﺑﺠﺎ‬ ‫وزﻧﻪ‬
‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮار‬ ‫ﮐﯿﻠﻮﮔﺮم=ﯾﮏ‬ ‫ﺑﻪ‬ ‫ﺷﺪه‬
‫ـﺎﻓﺌﯿﻦ‬‫ﮐـ‬ ‫ـﻞ‬‫ﻣﮑﻤـ‬ ‫ـﺎد‬‫ﺣـ‬ ‫ـﺮف‬‫ﻣﺼـ‬ ‫ـﺮارداد‬‫ﻗـ‬:
‫ﮐﭙﺴﻮل‬‫ﻫﺎي‬)500‫ﻣﯿﻠﯽ‬‫ﮐـﺎﻓﺌﯿﻦ‬ (‫ﮔﺮﻣـﯽ‬‫ﺳـﺎﺧﺖ‬
)‫ﻧﯿﺘﺮوﻣﺲ‬ ‫ﺷﺮﮐﺖ‬Nitro Mass(‫آﻣﺮﯾﮑـﺎ‬‫ﺗﺄﯾﯿـﺪ‬ ‫و‬
‫ﺗﻮﺳﻂ‬ ‫ﺷﺪه‬) ‫آﻣﺮﯾﮑـﺎ‬ ‫داروي‬ ‫و‬ ‫ﻏﺬا‬ ‫ﺳﺎزﻣﺎن‬FDA(
‫ﺗﻬﯿﻪ‬‫ﻣﮑﻤـﻞ‬ ‫)ﮔـﺮوه‬ ‫اﻓﺮاد‬ ‫وزن‬ ‫ﺗﻨﺎﺳﺐ‬ ‫ﺑﻪ‬ ‫و‬:6‫و‬9
‫ﻣﯿﻠﯽ‬‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬‫ﺑـﺪن‬ ‫وزن‬ ‫ﮐﯿﻠﻮﮔﺮم‬‫ﮐـﺎﻓﺌﯿﻦ‬‫و‬
‫ﺷـﺒﻪ‬ ‫ﮔﺮوه‬:‫دارو‬6‫ﻣﯿﻠـﯽ‬‫ﺑـﺪن‬ ‫وزن‬ ‫ازاي‬ ‫ﺑـﻪ‬ ‫ﮔـﺮم‬
‫ﺑﻪ‬ (‫دﮐﺴﺘﺮوز‬‫ﻣﺪت‬45‫ﻗﺮارداد‬ ‫اﻧﺠﺎم‬ ‫از‬ ‫ﻗﺒﻞ‬ ‫دﻗﯿﻘﻪ‬
‫ﺑـﻪ‬ ‫ﯾﮑﺴﺎن‬ ‫ﺻﺒﺤﺎﻧﻪ‬ ‫ﺻﺮف‬ ‫از‬ ‫ﭘﺲ‬ ‫و‬ ‫ﺗﻤﺮﯾﻨﯽ‬‫ﻫﻤـﺮاه‬
250‫ﻣ‬‫ﯿﻠﯽ‬.‫ﮔﺮﻓﺖ‬ ‫ﻗﺮار‬ ‫ﮔﺮوه‬ ‫ﻫﺮ‬ ‫اﺧﺘﯿﺎر‬ ‫در‬ ‫آب‬ ‫ﻟﯿﺘﺮ‬
‫ﺑﻪ‬‫ﻃﻮري‬‫ﺗﺤﻘﯿـﻖ‬ ‫در‬ ‫ﻣﺼـﺮﻓﯽ‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﻣﻘـﺎدﯾﺮ‬ ‫ﮐﻪ‬
‫داﻣﻨـﻪ‬ ‫در‬ ‫ﻗﺒﻠﯽ‬ ‫ﻣﻄﺎﻟﻌﺎت‬ ‫ﻧﺘﺎﯾﺞ‬ ‫اﺳﺎس‬ ‫ﺑﺮ‬ ،‫ﺣﺎﺿﺮ‬‫ي‬
) ‫اﺛﺮﮔﺬار‬3‫ﺗﺎ‬9‫ﻣﯿﻠﯽ‬‫ﮐﯿﻠـﻮﮔﺮم‬ ‫ﻫـﺮ‬ ‫ازاي‬ ‫ﺑـﻪ‬ ‫ﮔـﺮم‬
،‫ﺑﺪن‬ ‫وزن‬30‫اﻟﯽ‬60‫ﻗﺮارداد‬ ‫اﻧﺠﺎم‬ ‫از‬ ‫ﻗﺒﻞ‬ ‫دﻗﯿﻘﻪ‬
‫ﭘﻼﺳﻤﺎﯾ‬ ‫ﺳﻄﺢ‬ ‫ارﺗﻘﺎي‬ ‫ﺑﺮاي‬ ‫ﻧﯿﺎز‬ ‫ﻣﻮرد‬ (‫ﺗﻤﺮﯾﻨﯽ‬‫و‬ ‫ﯽ‬
‫ﺷـﺪ‬ ‫ﮔﺮﻓﺘـﻪ‬ ‫ﻧﻈـﺮ‬ ‫در‬ ‫ورزﺷـﮑﺎران‬ ‫ﻋﻤﻠﮑـﺮد‬ ‫ﺑﻬﺒﻮد‬
)16.(
‫ﺑـﺎ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﻗﺮارداد‬‫وزﻧـﻪ‬:‫ﻗـﺮارداد‬
‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬45‫ﻣﮑﻤـﻞ‬ ‫ﻣﺼﺮف‬ ‫از‬ ‫ﭘﺲ‬ ‫دﻗﯿﻘﻪ‬
‫و‬15‫ـﺎﻣﻞ‬‫ـ‬‫)ﺷ‬ ‫ـﻮﻣﯽ‬‫ـ‬‫ﻋﻤ‬ ‫ـﺮدن‬‫ـ‬‫ﮐ‬ ‫ـﺮم‬‫ـ‬‫ﮔ‬ ‫ـﻪ‬‫ـ‬‫دﻗﯿﻘ‬‫ـﮏ‬‫ـ‬‫ﯾ‬
‫ﺑـﺎ‬ ‫ﻫﻤـﺮاه‬ ‫دﻗﯿﻘﻪ‬ ‫ﭘﻨﺞ‬ ‫ﻃﯽ‬ ‫دوﯾﺪن‬ ‫ﮐﯿﻠﻮﻣﺘﺮ‬10‫دﻗﯿﻘـﻪ‬
‫ﻧﺮﻣﺸﯽ‬ ‫و‬ ‫ﮐﺸﺸﯽ‬ ‫ﺣﺮﮐﺎت‬‫اﺧﺘﺼﺎﺻﯽ‬ ‫ﮐﺮدن‬ ‫ﮔﺮم‬ ‫و‬ (
‫ﺑﻪ‬ ‫ﮐﺮدن‬ ‫ﮔﺮم‬ ‫ﺷﺎﻣﻞ‬ ‫ﮐﻪ‬‫ﻫـﺮ‬ ‫اﺑﺘـﺪاي‬ ‫در‬ ‫ﻣﺠﺰا‬ ‫ﻃﻮر‬
‫ﺗﮑﺮارﻫـﺎي‬ ‫ﺷﺎﻣﻞ‬ ‫ﮐﻪ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﺗﻤﺮﯾﻦ‬ ‫اﯾﺴﺘﮕﺎه‬12
‫اﻟﯽ‬15‫ﺑﺎ‬ ‫ﺗﺎﯾﯽ‬50‫اﻧﺠﺎم‬ ‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮار‬ ‫ﯾﮏ‬ ‫درﺻﺪ‬
.‫ﺷﺪ‬90،‫اﺧﺘﺼﺎﺻـﯽ‬ ‫ﮐـﺮدن‬ ‫ﮔﺮم‬ ‫اﺗﻤﺎم‬ ‫از‬ ‫ﺑﻌﺪ‬ ‫ﺛﺎﻧﯿﻪ‬
‫ﺑﺎ‬ ‫ﺑﺎوزﻧﻪ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﺗﻤﺮﯾﻦ‬ ‫ﻧﻮﺑﺖ‬ ‫ﺳﻪ‬ ‫اﯾﺴﺘﮕﺎه‬ ‫ﻫﺮ‬ ‫در‬
80‫ﺗﮑﺮار‬ ‫ﯾﮏ‬ ‫درﺻﺪ‬‫ﮐـﻪ‬ ‫واﻣﺎﻧﺪﮔﯽ‬ ‫ﺣﺪ‬ ‫ﺗﺎ‬ ‫ﺑﯿﺸﯿﻨﻪ‬
‫ﻧﻮﺑﺖ‬ ‫ﻫﺮ‬ ‫ﻣﯿﺎن‬60‫ﺗﺎ‬90‫ﻏﯿﺮﻓﻌﺎل‬ ‫اﺳﺘﺮاﺣﺖ‬ ‫ﺛﺎﻧﯿﻪ‬
‫ـﺘﮕﺎه‬‫ـ‬‫اﯾﺴ‬ ‫ـﺮ‬‫ـ‬‫ﻫ‬ ‫ـﺎم‬‫ـ‬‫اﺗﻤ‬ ‫از‬ ‫ـﺲ‬‫ـ‬‫ﭘ‬ .‫ـﻮد‬‫ـ‬‫ﺑ‬2‫ـﺎ‬‫ـ‬‫ﺗ‬3‫ـﻪ‬‫ـ‬‫دﻗﯿﻘ‬
‫ﺑﻪ‬ ‫ﺳﺎﻟﻦ‬ ‫در‬ ‫رﻓﺘﻦ‬ ‫راه‬ ‫ﺷﺎﻣﻞ‬ ‫ﻓﻌﺎل‬ ‫اﺳﺘﺮاﺣﺖ‬‫ﻣﻨﻈﻮر‬
) ‫ﺑﻮد‬ ‫ﺷﺪه‬ ‫ﮔﺮﻓﺘﻪ‬ ‫ﻧﻈﺮ‬ ‫در‬ ‫ﻗﻠﺐ‬ ‫ﺿﺮﺑﺎن‬ ‫ﮐﺎﻫﺶ‬15.(
‫ﻧﺤﻮه‬‫ﮐـﻪ‬ ‫ﺑـﻮد‬ ‫ﻗﺮاري‬ ‫ﺑﻪ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫اﻧﺠﺎم‬ ‫ي‬
‫ﺑﺰرگ‬ ‫ﻋﻀﻼت‬ ‫اﺑﺘﺪا‬‫ﮐﻮﭼﮏ‬ ‫ﻋﻀﻼت‬ ‫ﺳﭙﺲ‬ ‫و‬ ‫ﺗﺮ‬‫ﺗـﺮ‬
،‫زﯾﺮﺑﻐـﻞ‬ ‫ﮐﺸـﺶ‬ ،‫ﭘـﺎ‬ ‫ﺟﻠـﻮ‬ ،‫ﺳﯿﻨﻪ‬ ‫ﭘﺮس‬ ،‫ﭘﺎ‬ ‫)ﭘﺮس‬
(‫ﺑـﺎزو‬ ‫دوﺳـﺮ‬ ‫ﭘـﺮس‬ ‫و‬ ‫ﺳﺮﺷﺎﻧﻪ‬ ‫ﭘﺮس‬ ،‫درازوﻧﺸﺴﺖ‬
) ‫ﺷﻮﻧﺪ‬ ‫درﮔﯿﺮ‬12‫اﯾﺴـﺘﮕﺎه‬ ‫ﺗﻤـﺎم‬ ‫اﺗﻤﺎم‬ ‫از‬ ‫ﺑﻌﺪ‬ .(‫ﻫـﺎ‬
‫وﺳـﯿﻠﻪ‬ ‫ﺑـﻪ‬ ‫ﺧـﻮن‬ ‫ﻓﺸـﺎر‬ ،‫ﻗﻠـﺐ‬ ‫ﺿﺮﺑﺎن‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬‫ي‬
‫ﺳﻨﺞ‬ ‫ﺿﺮﺑﺎن‬ ‫دﺳﺘﮕﺎه‬) ‫ﭘﻮﻻر‬Polar Beat(‫ﻣﯿـﺰان‬ ‫و‬
‫ﻓﺸـﺎر‬ ‫درك‬)Rating of Perceived Exertion(
‫ﻣﯽ‬ ‫ﮐﻨﺘﺮل‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﻧﺎﺷﯽ‬‫ﺑﻪ‬ .‫ﺷﺪ‬‫اﻧﺘﻬﺎي‬ ‫در‬ ،‫ﻋﻼوه‬
‫ﻧﻮﺑﺖ‬ ‫ﺗﻤﺎم‬‫ﺑـﺮاي‬ ‫ﺗﮑﺮارﻫـﺎ‬ ‫ﺗﻌﺪاد‬ ‫اﯾﺴﺘﮕﺎه‬ ‫ﻫﺮ‬ ‫در‬ ‫ﻫﺎ‬
‫ﻣﻘﺎﯾﺴﻪ‬‫در‬ .‫ﮔﺮدﯾـﺪ‬ ‫ﺛﺒـﺖ‬ ‫ﺷﺪه‬ ‫اﻧﺠﺎم‬ ‫ﮐﺎر‬ ‫ﻣﯿﺰان‬ ‫ي‬

4. ‫راﻣ‬‫ﯿ‬‫ﻦ‬‫اﻣ‬‫ﯿ‬‫ﺮﺳﺎﺳﺎن‬‫ﻫﻤﮑﺎر‬ ‫و‬‫ان‬
‫ﻣﺠﻠﻪ‬‫ﻋﻠﻮم‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394http://rjms.iums.ac.ir
52
‫ﺧﺎﺗﻤﻪ‬‫ﺟﻠﺴﻪ‬ ‫ي‬‫ﻣـﺪت‬ ‫ﺑـﻪ‬ ‫ﻧﯿﺰ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ي‬
15.‫ﮔﺮدﯾﺪ‬ ‫اﺟﺮا‬ ‫ﻋﻤﻮﻣﯽ‬ ‫ﺳﺮدﮐﺮدن‬ ‫دﻗﯿﻘﻪ‬
‫ـﻊ‬‫ﺟﻤـ‬‫ـﻪ‬‫ﻧﻤﻮﻧـ‬ ‫آوري‬‫و‬ ‫ـﻮﻧﯽ‬‫ﺧـ‬ ‫ـﺮي‬‫ﮔﯿـ‬‫روش‬
‫اﻧــﺪازه‬‫ﮔﯿــﺮي‬:‫ﻧﻤﻮﻧــﻪ‬‫ورﯾــﺪ‬ ‫از‬ ‫ﺧــﻮﻧﯽ‬ ‫ﻫــﺎي‬
‫ﭘـﯿﺶ‬) ‫ـﯽ‬‫ـ‬‫آرﻧﺠ‬Antecubital vein‫ـﭗ‬‫ـ‬‫ﭼ‬ ‫ـﺖ‬‫ـ‬‫دﺳ‬ (
‫آزﻣﻮدﻧﯽ‬‫ﻣﺼـﺮف‬ ‫از‬ ‫)ﻗﺒـﻞ‬ ‫ﻣﺮﺣﻠـﻪ‬ ‫ﺳـﻪ‬ ‫ﻃﯽ‬ ‫در‬ ‫ﻫﺎ‬
،‫ﻣﮑﻤــﻞ‬45‫و‬ ‫ﻣﮑﻤــﻞ‬ ‫ﻣﺼــﺮف‬ ‫از‬ ‫ﭘــﺲ‬ ‫دﻗﯿﻘــﻪ‬
.‫ﺷـﺪ‬ ‫ﮔﺮﻓﺘـﻪ‬ (‫ﻣﻘـﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﭘﺲ‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬
5/3‫در‬ ‫ﺳـﺮم‬ ‫ﺟﺪاﺳﺎزي‬ ‫ﺟﻬﺖ‬ ‫ﺧﻮن‬ ‫از‬ ‫ﻟﯿﺘﺮ‬ ‫ﻣﯿﻠﯽ‬
‫ﻟﻮﻟﻪ‬‫ﺷ‬ ‫رﯾﺨﺘﻪ‬ ‫ﻣﺨﺼﻮص‬ ‫آزﻣﺎﯾﺶ‬‫ﻧﻤﻮﻧﻪ‬ ‫ﺳﭙﺲ‬ .‫ﺪ‬‫ﻫﺎ‬
‫ﺑﻪ‬‫ﻣﺪت‬15‫آزﻣﺎﯾﺸـﮕﺎﻫﯽ‬ ‫ﻣﺤـﯿﻂ‬ ‫دﻣﺎي‬ ‫در‬ ‫دﻗﯿﻘﻪ‬
25-22‫آن‬ ‫از‬ ‫ﭘﺲ‬ .‫ﺷﻮﻧﺪ‬ ‫ﻟﺨﺘﻪ‬ ‫ﺗﺎ‬ ‫ﺷﺪﻧﺪ‬ ‫داده‬ ‫ﻗﺮار‬
‫ﻧﻤﻮﻧﻪ‬ ‫ﺳﺮم‬) ‫ﺳـﺎﻧﺘﺮﯾﻔﯿﻮژ‬ ‫دﺳـﺘﮕﺎه‬ ‫ﺗﻮﺳﻂ‬ ‫ﻫﺎ‬3500
‫ﻣـﺪت‬ ‫ﺑﺮاي‬ ‫دﻗﯿﻘﻪ‬ ‫در‬ ‫دور‬10.‫ﺷـﺪ‬ ‫ﺟـﺪا‬ (‫دﻗﯿﻘـﻪ‬
‫ﻧﻤﻮﻧﻪ‬ ،‫ﺑﻌﺪي‬ ‫ﻣﺮاﺣﻞ‬ ‫اﻧﺠﺎم‬ ‫ﺑﺮاي‬‫دﻣـﺎي‬ ‫در‬ ‫ﻫﺎ‬70-
‫ﺳﺎﻧﺘﯽ‬ ‫درﺟﻪ‬‫ﺷﺪﻧﺪ‬ ‫داده‬ ‫ﻗﺮار‬ ‫ﮔﺮاد‬‫ﺷـﺎﺧﺺ‬ ‫ﻣﯿﺰان‬ .
‫اﻟﺘﻬـﺎﺑﯽ‬‫اﯾﻨﺘﺮﻟـﻮﮐﯿﻦ‬-6‫ﺳـﺮم‬‫ﮐﯿـﺖ‬ ‫از‬ ‫اﺳـﺘﻔﺎده‬ ‫ﺑـﺎ‬
) ‫اﻻﯾـﺰا‬ ‫دﺳـﺘﮕﺎه‬ ‫ﻣﺨﺼﻮص‬ELISA‫ﺷـﺮﮐﺖ‬ ‫ﺳـﺎﺧﺖ‬ (
‫ﺳﻦ‬ ‫ﻫﻠﻨﺪي‬) ‫اﻻﯾـﺰا‬ ‫روش‬ ‫ﮐﻤـﮏ‬ ‫ﺑﺎ‬ ‫ﮐﻮﯾﻦ‬Awareness
Technology, USA‫اﻧﺪازه‬ (.‫ﺷﺪ‬ ‫ﮔﯿﺮي‬‫ﺑﻪ‬‫ﺗﻤﺎم‬ ،‫ﻋﻼوه‬
‫رﻃﻮﺑـﺖ‬ ‫ﺑـﺎ‬ ‫اﺳـﺘﺎﻧﺪارد‬ ‫ﺷﺮاﯾﻂ‬ ‫در‬ ‫ﭘﮋوﻫﺶ‬ ‫ﻣﺮاﺣﻞ‬
‫ـﺒﯽ‬‫ـ‬‫ﻧﺴ‬55-50‫ـﺎي‬‫ـ‬‫دﻣ‬ ،‫ـﺪ‬‫ـ‬‫درﺻ‬28-26‫ـﻪ‬‫ـ‬‫درﺟ‬‫ي‬
‫ﺳﺎﻧﺘﯽ‬‫ﺳﺎﻋﺖ‬ ‫در‬ ‫و‬ ‫ﮔﺮاد‬8‫اﻟﯽ‬11.‫ﺷﺪ‬ ‫اﻧﺠﺎم‬ ‫ﺻﺒﺢ‬
‫روش‬‫آﻣـﺎري‬ ‫ﺗﺤﻠﯿـﻞ‬ ‫و‬ ‫ﺗﺠﺰﯾـﻪ‬ ‫ﻫﺎي‬:‫اﺑﺘـﺪا‬
‫داده‬ ‫ـﯽ‬‫ـ‬‫ﻃﺒﯿﻌ‬ ‫ـﻌﯿﺖ‬‫ـ‬‫وﺿ‬‫ـﺎ‬‫ـ‬‫ﻫ‬‫ـﻦ‬‫ـ‬‫ﻫﻤﮕ‬ ‫و‬ ‫ـﯽ‬‫ـ‬‫ﻃﺒﯿﻌ‬ ‫ي‬-
‫ـﺎﻧﮕﯿﻦ‬‫ـ‬‫)ﻣﯿ‬‫از‬ ‫ـﺘﻔﺎده‬‫ـ‬‫اﺳ‬ ‫ـﺎ‬‫ـ‬‫ﺑ‬ (‫ـﺘﺎﻧﺪارد‬‫ـ‬‫اﺳ‬ ‫ـﺮاف‬‫ـ‬‫اﻧﺤ‬
‫آزﻣﻮن‬‫ﮐﻠﻤﻮﮔﺮوف‬-‫اﺳﻤﯿﺮﻧﻮف‬‫ﺳﭙﺲ‬ .‫ﺷﺪ‬ ‫ﺑﺮرﺳﯽ‬
‫ﺷﺎﺧﺺ‬ ‫از‬ ‫ﯾﮏ‬ ‫ﻫﺮ‬ ‫ﺗﻐﯿﯿﺮات‬‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﺮاﺣﻞ‬ ‫ﻃﯽ‬ ‫ﻫﺎ‬
‫اﻧﺪازه‬‫ﮔﯿﺮي‬‫آزﻣﻮن‬ ‫ﺑﺎ‬‫ﻫﺎي‬‫و‬ ‫ﻣﮑـﺮر‬ ‫وارﯾﺎﻧﺲ‬ ‫ﺗﺤﻠﯿﻞ‬
‫ﺑـﻮﻧﻔﺮوﻧﯽ‬ ‫آزﻣﻮن‬ ‫ﭘﺲ‬‫ﺑﺮرﺳـﯽ‬‫ﮔﺮدﯾـﺪ‬‫اﺧﺘﻼﻓـﺎت‬ .
‫ﮔﺮوﻫﯽ‬ ‫ﺑﯿﻦ‬‫داده‬‫اﺑﺘﺪاﯾﯽ‬ ‫ﻫﺎي‬‫آزﻣﻮن‬ ‫ﺑﺎ‬ ‫ﻧﯿﺰ‬‫ﺗﺤﻠﯿﻞ‬
‫ﻃﺮﻓـﻪ‬ ‫ﯾﮏ‬ ‫وارﯾﺎﻧﺲ‬‫ﮔﺮوﻫـﯽ‬ ‫ﺳـﻪ‬ ‫ي‬‫ﺗﻌﯿـﯿﻦ‬‫ﺷـﺪ‬.
‫ﻫﻤﻪ‬‫ﻋﻤﻠﯿﺎت‬ ‫ي‬‫ﺗﺤﻠﯿـﻞ‬ ‫و‬‫ﺳـﻄﺢ‬ ‫در‬ ‫آﻣـﺎري‬ ‫ﻫـﺎي‬
‫ﻣﻌﻨﯽ‬‫ﻧـﺮم‬ ‫از‬ ‫اﺳﺘﻔﺎده‬ ‫ﺑﺎ‬ ‫درﺻﺪ‬ ‫ﭘﻨﺞ‬ ‫داري‬‫اﻓﺰارﻫـﺎي‬
‫ـﺎري‬‫ـ‬‫آﻣ‬SPSS/PASW19‫و‬Excel2010‫ـﺎم‬‫ـ‬‫اﻧﺠ‬
‫ﮔﺮدﯾﺪ‬.‫ﻋﻮاﻣـﻞ‬ ‫از‬ ‫ﯾـﮏ‬ ‫ﻫـﺮ‬ ‫اﺛـﺮ‬ ‫ﺳـﻬﻢ‬ ،‫ﻋـﻼوه‬ ‫ﺑـﻪ‬
‫ﻣﺪاﺧﻠﻪ‬) ‫ُﻣﮕـﺎ‬‫ا‬ ‫ﻣﺠـﺬور‬ ‫از‬ ‫اﺳـﺘﻔﺎده‬ ‫ﺑﺎ‬ ‫ﮔﺮ‬Omega
squared.‫ﮔﺮدﯾﺪ‬ ‫ﺗﻌﯿﯿﻦ‬ (
‫ﯾﺎﻓﺘﻪ‬‫ﻫﺎ‬
‫ﻫـﯿﭻ‬ ‫ﮐـﻪ‬ ‫داد‬ ‫ﻧﺸـﺎن‬ ‫ﺣﺎﺿﺮ‬ ‫ﭘﮋوﻫﺶ‬ ‫ﻧﺘﺎﯾﺞ‬‫ﮔﻮﻧـﻪ‬
‫ﻣﻌﻨﯽ‬ ‫ﺗﻔﺎوت‬‫داري‬‫وﯾﮋﮔﯽ‬ ‫ﺑﯿﻦ‬‫ﻣﯿـﺰان‬ ‫و‬ ‫ﻓﺮدي‬ ‫ﻫﺎي‬
) ‫ـﺪه‬‫ـ‬‫ﺷ‬ ‫ـﺎم‬‫ـ‬‫اﻧﺠ‬ ‫ـﺎر‬‫ـ‬‫ﮐ‬Work of rate‫ـﺮوه‬‫ـ‬‫ﮔ‬ ‫ـﯿﻦ‬‫ـ‬‫ﺑ‬ (
‫ﺷﺒﻪ‬‫ﮔﺮوه‬ ‫و‬ ‫دﮐﺴﺘﺮوز‬ ‫داروي‬‫ﮐﻨﻨـﺪه‬ ‫ﻣﺼﺮف‬ ‫ﻫﺎي‬‫ي‬
‫)ﺟﺪول‬ ‫ﻧﺪارد‬ ‫وﺟﻮد‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﮑﻤﻞ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬
1‫ﻃﻮري‬ ‫ﺑﻪ‬ .(‫ﯾـﮏ‬ ‫ﻃـﯽ‬ ‫ﺷـﺪه‬ ‫اﻧﺠﺎم‬ ‫ﮐﺎر‬ ‫ﻣﯿﺰان‬ ‫ﮐﻪ‬
‫ﺑﺎ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫ﺟﻠﺴﻪ‬80‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﺗﮑﺮار‬ ‫ﯾﮏ‬ %
‫واﻣﺎﻧﺪه‬ ‫ﺣﺪ‬ ‫ﺗﺎ‬‫ﺑﻪ‬ ‫ﮔﯽ‬‫ﺗﺮ‬‫ﮔﺮوه‬ ‫ﺑﺮاي‬ ‫ﺗﯿﺐ‬‫ﺷﺒﻪ‬ ‫ﻫﺎي‬‫دارو‬
‫ﮐﻨﻨﺪه‬ ‫ﻣﺼﺮف‬ ‫و‬‫ﻣﻘﺎدﯾﺮ‬ ‫ي‬6‫و‬9‫ﻣﯿﻠﯽ‬‫وزن‬ ‫در‬ ‫ﮔﺮم‬
‫ـﻪ‬‫ـ‬‫ﺑ‬ ‫ـﺎﻓﺌﯿﻦ‬‫ـ‬‫ﮐ‬ ‫ـﺪن‬‫ـ‬‫ﺑ‬‫ـﺐ‬‫ـ‬‫ﺗﺮﺗﯿ‬05/18767/11321،
37/22123/11478‫و‬12/20450/11563
.‫ﺑﻮد‬ ‫ﮐﯿﻠﻮﮔﺮم‬‫ﻣﻄﺎﻟﻌـﻪ‬ ‫ﻧﺘـﺎﯾﺞ‬ ،‫ﻫﻤﭽﻨﯿﻦ‬‫ﺣﺎﺿـﺮ‬ ‫ي‬
‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫داد‬ ‫ﻧﺸﺎن‬
)6‫و‬9‫ﻣﯿﻠﯽ‬‫ﻫﺮﮐﯿﻠـﻮﮔ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬‫ﺑـﺪن‬ ‫وزن‬ ‫ﺮم‬‫در‬ (
) ‫ﭘﺎﯾﻪ‬ ‫ﺣﺎﻟﺖ‬45‫ﺑـﺮ‬ (‫ﻣﮑﻤـﻞ‬ ‫ﻣﺼﺮف‬ ‫از‬ ‫ﭘﺲ‬ ‫دﻗﯿﻘﻪ‬
‫اﯾﻨﺘﺮﮐﻮﮐﯿﻦ‬ ‫ﻓﻌﺎﻟﯿﺖ‬-6‫ﻣﻌﻨـﯽ‬ ‫ﺗـﺄﺛﯿﺮ‬ ‫ﺳـﺮﻣﯽ‬‫داري‬
‫ﻣﯽ‬) ‫ﮔﺬارد‬038/0=p‫)ﺟـﺪول‬ (2‫ﺑـﻪ‬ .(‫ﻃـﻮري‬‫ﮐـﻪ‬
‫ﭘﺎﯾـﻪ‬ ‫ﺣﺎﻟـﺖ‬ ‫در‬ ‫ﺑـﻮﻧﻔﺮوﻧﯽ‬ ‫ﺗﻌﻘﯿﺒـﯽ‬ ‫آزﻣـﻮن‬ ‫ﻧﺘﺎﯾﺞ‬
‫ﺟﺪول‬1-‫وﯾﮋﮔﯽ‬‫آزﻣﻮدﻧﯽ‬ ‫ﻓﺮدي‬ ‫ﻫﺎي‬‫ﻫﺎ‬
‫ﺷﺎﺧﺺ‬‫ﻣﻄﺎﻟﻌﻪ‬ ‫ﻣﻮرد‬ ‫ﻫﺎي‬‫ﮔﺮوه‬‫ﻣﻄﺎﻟﻌﻪ‬ ‫ﻣﻮرد‬ ‫ﻫﺎي‬
‫ﺷﺒﻪ‬‫دﮐﺴﺘﺮوز‬ ‫دارو‬
)6‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬
‫ﮐﺎﻓﺌﯿﻦ‬
)6‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬
‫ﮐﺎﻓﺌﯿﻦ‬
)9‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬
(‫)ﺳﺎل‬ ‫ﺳﻦ‬94/030/2171/150/2171/160/21
(‫وزن)ﮐﯿﻠﻮﮔﺮم‬89/750/8150/410/7971/540/81
‫ﻗﺪ)ﺳﺎﻧﺘﯽ‬(‫ﻣﺘﺮ‬85/665/18640/270/18493/270/186
‫ﺗﻮده‬ ‫ﺷﺎﺧﺺ‬(‫ﻣﺮﺑﻊ‬ ‫ﻣﺘﺮ‬ ‫در‬ ‫)ﮐﯿﻠﻮﮔﺮم‬ ‫ﺑﺪن‬ ‫ي‬22/120/2325/195/2241/130/23
‫درﺻﺪ‬‫ﺑﺪن‬ ‫ﭼﺮﺑﯽ‬21/270/1079/320/1044/350/10
‫ﻣﺼﺮﻓﯽ‬ ‫اﻧﺮژي‬24(‫روز‬ /‫)ﮐﯿﻠﻮﮐﺎﻟﺮي‬ ‫ﺳﺎﻋﺘﻪ‬46/152±30/350763/184±10/344987/142±00/3480
‫روزاﻧﻪ‬ ‫ﻣﺼﺮف‬‫)ﻣﯿﻠﯽ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ي‬(‫روز‬ /‫ﮔﺮم‬84/15±02/9924/17±66/9810/14±00/96

5. ‫ﺗﺄﺛ‬‫ﯿ‬‫ﺮ‬‫ﺣﺎد‬‫ﺗﻤﺮ‬‫ﯾ‬‫ﻨﺎت‬‫ﻣﻘﺎوﻣﺘ‬‫ﯽ‬‫واﻣﺎﻧﺪه‬‫ﺳﺎز‬‫و‬‫ﻣﺼﺮف‬‫ﻣﻘﺎد‬‫ﯾ‬‫ﺮ‬‫ﻣﺨﺘﻠﻒ‬‫ﮐﺎﻓﺌ‬‫ﯿ‬‫ﻦ‬‫ﺑﺮ‬‫ﭘﺎﺳﺦ‬‫ا‬‫ﯾ‬‫ﻨﺘﺮﻟﻮﮐ‬‫ﯿ‬‫ﻦ‬-6
http://rjms.iums.ac.ir‫ﻋﻠﻮم‬ ‫ﻣﺠﻠﻪ‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394
53
‫ﺣـﺎد‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫داد‬ ‫ﻧﺸﺎن‬ (‫دو‬ ‫و‬ ‫ﯾﮏ‬ ‫)ﻣﺮاﺣﻞ‬6‫و‬
9‫ﻣﯿﻠﯽ‬‫ﮐﯿﻠـﻮﮔﺮم‬ ‫ﻫـﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﮔﺮم‬‫وزن‬ ‫از‬
‫ﺑﻪ‬ ‫ﺑﺪن‬(‫ُﻣﮕـﺎ‬‫ا‬) ‫اﺛـﺮ‬ ‫ﺳـﻬﻢ‬ ‫ﺑـﺎ‬ ‫ﺗﺮﺗﯿﺐ‬79/0‫و‬81/0
‫ﻣﻌﻨـﯽ‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬‫اﯾﻨﺘﺮﻟـﻮﮐﯿﻦ‬ ‫دار‬-6‫ﺳـﺮﻣﯽ‬
‫ﻣﯽ‬) ‫ﺷﻮد‬042/0=p.(
‫ﻓﻌﺎﻟﯿـﺖ‬ ‫ﺟﻠﺴـﻪ‬ ‫ﯾﮏ‬ ‫ﮐﻪ‬ ‫داد‬ ‫ﻧﺸﺎن‬ ‫ﻧﺘﺎﯾﺞ‬ ،‫ﻫﻤﭽﻨﯿﻦ‬
‫ﺷﺪت‬ ‫)ﺑﺎ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬80‫ﺗـﺎ‬ ‫ﺑﯿﺸـﯿﻨﻪ‬ ‫ﺗﮑـﺮار‬ ‫ﯾـﮏ‬ ‫درﺻﺪ‬
‫اﺛـﺮ‬ ‫ﺳـﻬﻢ‬ ‫ﺑﺎ‬ (‫واﻣﺎﻧﺪﮔﯽ‬ ‫ﺣﺪ‬94/0)12/95(‫درﺻـﺪي‬
‫ﻣﻌﻨﯽ‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﺎﻋﺚ‬‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫دار‬-6‫ﺑﻼﻓﺎﺻـﻠﻪ‬ ‫ﺳـﺮم‬
‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﭘﺲ‬‫ﺷـﺒﻪ‬ ‫ﮔـﺮوه‬ ‫در‬‫ﺷـﺪ‬ ‫دارو‬)028/0=p(.
‫ﺑﻪ‬‫ﻣﻄﺎﻟﻌـﻪ‬ ‫ﻧﺘـﺎﯾﺞ‬ ،‫ﻋﻼوه‬‫ﺣـﺎﮐﯽ‬ ‫ﺣﺎﺿـﺮ‬ ‫ي‬‫ﮐـﻪ‬ ‫اﺳـﺖ‬
‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﺑـﺪن‬ ‫وزن‬ ‫در‬ ‫ﮔﺮم‬
‫ﺑﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬‫اﺛﺮ‬ ‫ﺳﻬﻢ‬ ‫ﺑﺎ‬ ‫ﺗﺮﺗﯿﺐ‬98/0‫و‬99/0‫ﺑﻪ‬‫ﻃـﻮر‬
‫ﻣﻌﻨﯽ‬) ‫داري‬50/107‫و‬92/110‫ﺑﺎﻋـﺚ‬ (‫درﺻﺪي‬
‫ﺑﻼﻓﺎﺻـﻠﻪ‬ ‫اﻟﺘﻬـﺎﺑﯽ‬ ‫ﺷـﺎﺧﺺ‬ ‫اﻓﺰاﯾﺸﯽ‬ ‫ﭘﺎﺳﺦ‬ ‫ﺗﺸﺪﯾﺪ‬
‫واﻣﺎﻧـﺪه‬ ‫ﻣﻘـﺎوﻣﺘﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﭘﺲ‬‫ﻣـﯽ‬ ‫ﺳـﺎز‬‫ﮔـﺮدد‬
)019/0p=‫ﺑـﻪ‬ .(‫ـﺦ‬‫ـ‬‫ﭘﺎﺳ‬ ‫ـﺮات‬‫ـ‬‫ﺗﻐﯿﯿ‬ ‫درﺻـﺪ‬ ،‫ـﺎرﺗﯽ‬‫ـ‬‫ﻋﺒ‬
‫ﺷﺎﺧﺺ‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﺗﻤﺮﯾﻦ‬ ‫ﻣﺘﻌﺎﻗﺐ‬ ‫اﻟﺘﻬﺎﺑﯽ‬
‫ﮔﺮوه‬ ‫در‬‫ﮐﻨﻨﺪه‬ ‫ﻣﺼﺮف‬ ‫ﻫﺎي‬‫ي‬6‫و‬9‫ﻣﯿﻠﯽ‬‫در‬ ‫ﮔـﺮم‬
‫ﺷـﺒﻪ‬ ‫ﮔـﺮوه‬ ‫از‬ ‫ﺑﯿﺸـﺘﺮ‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﺑﺪن‬ ‫وزن‬‫ﺑـﻮد‬ ‫دارو‬
‫)ﺟﺪول‬2‫ﺷﮑﻞ‬ ‫و‬1‫ﺿـﺮوري‬ ‫ﻧﮑﺘﻪ‬ ‫اﯾﻦ‬ ‫ذﮐﺮ‬ ‫اﻟﺒﺘﻪ‬ .(
‫اﻟﺘﻬـﺎﺑﯽ‬ ‫ﭘﺎﺳـﺦ‬ ‫ﺗﺸـﺪﯾﺪ‬ ‫ﻣﯿـﺰان‬ ‫ﻟﺤـﺎظ‬ ‫از‬ ‫ﮐﻪ‬ ‫اﺳﺖ‬
‫واﻣﺎﻧــﺪه‬ ‫ﻣﻘــﺎوﻣﺘﯽ‬ ‫ﺗﻤــﺮﯾﻦ‬ ‫از‬ ‫ﻧﺎﺷــﯽ‬‫ﻣﯿــﺎن‬ ‫ﺳــﺎز‬
‫ﮔﺮوه‬‫ﮐﻨﻨﺪه‬ ‫ﻣﺼﺮف‬ ‫ﻫﺎي‬‫ﺣﺎد‬ ‫ي‬6‫و‬9‫ﻣﯿﻠﯽ‬‫در‬ ‫ﮔﺮم‬
‫ﻫـﯿﭻ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺑﺪن‬ ‫وزن‬‫ﻣﻌﻨـﯽ‬ ‫ﺗﻔـﺎوت‬ ‫ﮔﻮﻧـﻪ‬‫داري‬
) ‫ﻧﮕﺮدﯾﺪ‬ ‫ﻣﺸﺎﻫﺪه‬05/0p>.(
‫ﻧﺘﯿﺠﻪ‬ ‫و‬ ‫ﺑﺤﺚ‬‫ﮔﯿﺮي‬
‫ﮐـﻪ‬ ‫داد‬ ‫ﻧﺸـﺎن‬ ‫ﺗﺤﻘﯿـﻖ‬ ‫اﯾﻦ‬ ‫ﻧﺘﺎﯾﺞ‬‫ﺣـﺎد‬ ‫ﻣﺼـﺮف‬
‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬) ‫ﭘﺎﯾﻪ‬ ‫ﺣﺎﻟﺖ‬ ‫در‬45‫دﻗﯿﻘـﻪ‬
(‫ﻣﺼــﺮف‬ ‫از‬ ‫ﭘــﺲ‬‫ﺑــﺮ‬‫اﻟﺘﻬــﺎﺑﯽ‬ ‫ﺷــﺎﺧﺺ‬ ‫ﭘﺎﺳــﺦ‬
‫)اﯾﻨﺘﺮﻟــﻮﮐﯿﻦ‬-6‫ﺳــﺮم‬(‫ﻣﻌﻨــﯽ‬ ‫ﺗــﺄﺛﯿﺮ‬.‫دارد‬ ‫داري‬
‫ﺑﻪ‬‫ﺣﺎد‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﻣﺼﺮف‬ ،‫ﻋﺒﺎرﺗﯽ‬6‫و‬9‫ﻣﯿﻠﯽ‬‫ﮔﺮم‬‫ﺑﻪ‬
‫ﮔﺮم‬ ‫ﮐﯿﻠﻮ‬ ‫ﻫﺮ‬ ‫ازاي‬‫ﺑﺪن‬ ‫وزن‬‫ﭘـﮋوﻫﺶ‬ ‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬
‫ﺟﺪول‬2-‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﺗﻐﯿﯿﺮات‬-6‫اﻧﺪازه‬ ‫ﻣﺮﺣﻠﻪ‬ ‫ﺳﻪ‬ ‫ﻃﯽ‬ ‫در‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬ ‫ﻣﺮدان‬ ‫ﺳﺮﻣﯽ‬‫ﮔﯿﺮي‬
‫ﺷﺎﺧﺺ‬‫ﻣﻄﺎﻟﻌﻪ‬ ‫ﻣﻮرد‬ ‫ﻫﺎي‬‫ﮔﺮوه‬‫ﻫﺎ‬‫ﭘﺎﯾﻪ‬ ‫ﺣﺎﻟﺖ‬45‫از‬ ‫ﭘﺲ‬ ‫دﻗﯿﻘﻪ‬‫ﻣﮑﻤﻞ‬‫دﻫﯽ‬‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﭘﺲ‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬-6‫ﺳﺮم‬
‫ﻣﯿﻠﯽ‬ /‫)ﭘﯿﮑﻮﮔﺮم‬(‫ﻟﯿﺘﺮ‬
‫ﺷﺒﻪ‬) ‫دﮐﺴﺘﺮوز‬ ‫دارو‬6‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬21/1  19/023/1  25/040/2  27/0 *
)‫ﮐﺎﻓﺌﯿﻦ‬6‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬20/1  21/039/1  66/0 *49/2  34/0 *
) ‫ﮐﺎﻓﺌﯿﻦ‬9‫ﻣﯿﻠﯽ‬(‫ﮔﺮم‬19/1  20/044/1  88/0 *51/2  49/0 *
‫ﮔﺮوﻫﯽ‬ ‫ﺑﯿﻦ‬ ‫اﺣﺘﻤﺎل‬ ‫ﻣﻘﺪار‬450/0†041/0†002/0
‫ﻣﻌﻨﯽ‬‫ﺳﻄﺢ‬ ‫در‬ ‫ﮔﺮوﻫﯽ‬ ‫درون‬ ‫داري‬05/0†‫ﻣﻌﻨﯽ‬‫ﺳﻄﺢ‬ ‫در‬ ‫ﮔﺮوﻫﯽ‬ ‫ﺑﯿﻦ‬ ‫داري‬05/0 *
‫ﺷﮑﻞ‬1-‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﺗﻐﯿﯿﺮات‬ ‫ﻣﯿﺰان‬-6‫اﻧﺪازه‬ ‫ﻣﺮاﺣﻞ‬ ‫ﻃﯽ‬ ‫ﻣﻄﺎﻟﻌﻪ‬ ‫ﻣﻮرد‬ ‫ﮔﺮوه‬ ‫ﺳﻪ‬ ‫در‬ ‫ﺳﺮﻣﯽ‬‫ﮔﯿﺮي‬
†‫ﻣﻌﻨﯽ‬) ‫ﺳﻄﺢ‬ ‫در‬ ‫ﮔﺮوﻫﯽ‬ ‫درون‬ ‫داري‬05/0p<(.

6. ‫راﻣ‬‫ﯿ‬‫ﻦ‬‫اﻣ‬‫ﯿ‬‫ﺮﺳﺎﺳﺎن‬‫ﻫﻤﮑﺎر‬ ‫و‬‫ان‬
‫ﻣﺠﻠﻪ‬‫ﻋﻠﻮم‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394http://rjms.iums.ac.ir
54
‫ﺑﻪ‬ ‫ﺣﺎﺿﺮ‬‫اﻓﺰاﯾﺶ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫ﺗﺮﺗﯿﺐ‬83/15‫و‬02/21
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﻣﯿﺰان‬ ‫درﺻﺪي‬-6‫ﭘﺎﯾﻪ‬ ‫ﺳﺮم‬‫ﻣـﺮدان‬ ‫ي‬
‫اﯾﻦ‬ .‫ﮔﺮدﯾﺪ‬ ‫واﻟﯿﺒﺎﻟﯿﺴﺖ‬‫ﯾﺎﻓﺘـﻪ‬‫ﻫـﺎ‬‫ﭘﺎﯾـﻪ‬ ‫ﺣﺎﻟـﺖ‬ ‫در‬
‫ﺗﺄﯾﯿﺪ‬‫ﺑﺮ‬ ‫ي‬‫ﻧﺘﺎﯾﺞ‬‫ﻣ‬) ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫ودﯾﮏ‬ ‫ﻄﺎﻟﻌﺎت‬17(
) ‫ﻫﻤﮑــﺎران‬ ‫و‬ ‫ُﻫﺘــﺎ‬‫ا‬ ‫و‬18(‫ـﯽ‬‫ـ‬‫ﻣﺒﻨـ‬‫ﺑــﺮ‬‫ـﺰاﯾﺶ‬‫ـ‬‫اﻓـ‬
‫ﺷﺎﺧﺺ‬‫ﻣﺼﺮف‬ ‫ﻣﺘﻌﺎﻗﺐ‬ ‫ﭘﺎﯾﻪ‬ ‫ﺣﺎﻟﺖ‬ ‫در‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬
‫ﮐﺎﻓﺌﯿﻨﯽ‬ ‫ﺗﺮﮐﯿﺒﺎت‬.‫اﺳﺖ‬‫ﯾﺎﻓﺘـﻪ‬ ‫ﮐﻪ‬ ‫ﺣﺎﻟﯽ‬ ‫در‬‫ﻫـﺎي‬
‫ﺑﺎ‬ ‫ﺣﺎﺿﺮ‬ ‫ﭘﮋوﻫﺶ‬‫ﻧﺘﺎﯾﺞ‬‫ﻫﻤﮑـﺎران‬ ‫و‬ ‫ﮐﻤـﭗ‬ ‫ﺗﺤﻘﯿﻖ‬
)19) ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫آرﺳﻨﺎت‬ ‫و‬ (20‫ﺗﻀﺎد‬ ‫در‬ (‫اﺳـﺖ‬.
‫ﺑﻪ‬‫ﻃﻮري‬،‫ﮐﻪ‬‫آزﻣﻮدﻧﯽ‬ ‫ﻧﻮع‬‫اﺳﺘﻔﺎده‬ ‫ﻣﻮرد‬‫و‬‫ﻗـﺮارداد‬
‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﮑﻤﻞ‬ ‫ﻣﺼﺮف‬‫ﻣـﯽ‬‫دﻻﯾـﻞ‬ ‫ﺟﻤﻠـﻪ‬ ‫از‬ ‫ﺗﻮاﻧـﺪ‬
‫ﻧﺘﯿﺠﻪ‬ ‫ﺗﻀﺎد‬ ‫و‬ ‫ﺗﻔﺎوت‬ ‫اﺣﺘﻤﺎﻟﯽ‬‫ي‬‫ﻣﻄﺎﻟﻌﻪ‬‫ﺣﺎﺿـﺮ‬ ‫ي‬
‫ﯾﺎﻓﺘﻪ‬ ‫ﺑﺎ‬.‫ﺑﺎﺷـﺪ‬ ‫اﻟـﺬﮐﺮ‬ ‫ﻓـﻮق‬ ‫ﻣﻄﺎﻟﻌﺎت‬ ‫ﻫﺎي‬‫اﯾـﻦ‬ ‫در‬
،‫راﺳﺘﺎ‬‫ﯾﺎﻓﺘﻪ‬ ‫از‬ ‫ﺑﺮﺧﯽ‬‫ﭼﻨـﯿﻦ‬ ‫اﺧﯿـﺮ‬ ‫ﻣﻄﺎﻟﻌـﺎت‬ ‫ﻫﺎي‬
‫ـﯽ‬‫ـ‬‫ﻣـ‬ ‫ـﻮان‬‫ـ‬‫ﻋﻨـ‬‫ـﺎت‬‫ـ‬‫ﺗﺮﮐﯿﺒـ‬ ‫ـﺮف‬‫ـ‬‫ﻣﺼـ‬ ‫ـﻪ‬‫ـ‬‫ﮐـ‬ ‫ـﺪ‬‫ـ‬‫ﻧﻤﺎﯾﻨـ‬
‫ﻣﺘﯿﻞ‬‫اﻓـﺮاد‬ ‫در‬ (‫ﮐـﺎﻓﺌﯿﻦ‬ ‫و‬ ‫ﻗﻬﻮه‬ ‫)ازﺟﻤﻠﻪ‬ ‫ﮔﺰاﻧﺘﯿﻨﯽ‬
‫ﺗﺮﮐﯿﺒـﺎت‬ ‫اﯾﻨﮕﻮﻧـﻪ‬ ‫روزاﻧـﻪ‬ ‫ﻣﺼـﺮف‬ ‫ﺑﻪ‬ ‫ﮐﺮده‬ ‫ﻋﺎدت‬
‫ﻧﯿـﺰ‬ ‫آرﺳـﻨﺎت‬ ‫و‬ ‫ﮐﻤﭗ‬ ‫ﭘﮋوﻫﺶ‬ ‫دو‬ ‫ﻫﺮ‬ ‫در‬ ‫)ﭼﻨﺎﻧﭽﻪ‬
‫اﯾﺰوﻓـﺮم‬ ‫ﻣﺜﺒـﺖ‬ ‫ﺑﯿـﺎن‬ ‫ﺑـﻪ‬ ‫ﻣﻨﺠـﺮ‬ (‫ﺑﻮد‬ ‫ﭼﻨﯿﻦ‬‫ﻫـﺎي‬
‫ﮔﯿﺮﻧــﺪه‬‫ﺑــﺮ‬ ‫و‬ ‫درون‬ ‫ﻫــﺎي‬‫آدﻧــﻮزﯾﻨﯽ‬ ‫ﺳــﻠﻮﻟﯽ‬ ‫ون‬
‫ـﯽ‬‫ـ‬‫ﻣ‬) ‫ـﺮدد‬‫ـ‬‫ﮔ‬8،9‫و‬21.(‫ـﺪه‬‫ـ‬‫ﮔﯿﺮﻧ‬‫در‬ ‫ـﻮزﯾﻨﯽ‬‫ـ‬‫آدﻧ‬ ‫ـﺎي‬‫ـ‬‫ﻫ‬
‫ﻋﺼـﺒﯽ‬ ،‫ﻋﺮوﻗـﯽ‬ ‫و‬ ‫ﻗﻠﺒﯽ‬ ‫دﺳﺘﮕﺎه‬ ‫ﺟﻤﻠﻪ‬ ‫از‬ ‫ﺑﺪن‬ ‫ﺳﺮﺗﺎﺳﺮ‬
‫ﭼﺮﺑﯽ‬ ‫ﺑﺎﻓﺖ‬ ‫و‬ ‫ﮔﻮارش‬ ،‫ﮐﻠﯿﻮي‬ ،‫اﺳﮑﻠﺘﯽ‬ ،‫ﺗﻨﻔﺴﯽ‬ ،‫ﻣﺮﮐﺰي‬
) ‫اﺳﺖ‬ ‫ﻣﻮﺟﻮد‬22‫ﺑﻪ‬ .(‫ﻃﻮري‬‫ﮔﯿﺮﻧﺪه‬ ‫اﯾﻦ‬ ‫ﮐﻪ‬‫ﻧﻘﺶ‬ ‫ﻫﺎ‬‫ﻫﺎي‬
‫ﻣـﯽ‬ ‫ﺑـﺎزي‬ ‫ﺑـﺪن‬ ‫در‬ ‫ﻣﺘﻔﺎوﺗﯽ‬‫ﯾـﺎ‬ ‫واﺑﺴـﺘﻪ‬ ‫ﮔـﺎﻫﯽ‬ .‫ﮐﻨﻨـﺪ‬
‫ـﺘﻪ‬‫ـ‬‫ﻏﯿﺮواﺑﺴ‬‫ـﻮي‬‫ـ‬‫ﺣﻠﻘ‬ ‫ـﻔﺎت‬‫ـ‬‫ﻣﻮﻧﻮﻓﺴ‬ ‫ـﻮزﯾﻦ‬‫ـ‬‫آدﻧ‬ ‫ـﯿﺮ‬‫ـ‬‫ﻣﺴ‬ ‫ـﻪ‬‫ـ‬‫ﺑ‬
)cAMP‫ﻣﯽ‬ ‫داده‬ ‫ﻧﺴﺒﺖ‬ () ‫ﺷﻮﻧﺪ‬22‫اﺛـﺮات‬ ‫ﺑـﺮ‬ ‫ﻋﻼوه‬ .(
‫ﮔﯿﺮﻧﺪه‬ ‫اﯾﻦ‬ ‫ﮐﻪ‬ ‫ﻣﺘﻌﺪدي‬‫ﺑﺎﻓﺖ‬ ‫در‬ ‫ﻫﺎ‬‫از‬ ‫ﺑﺪن‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻫﺎي‬
‫ﺑﺮﺟﺴـﺘﻪ‬ ‫ﻧﻘﺶ‬ ،‫دارﻧﺪ‬ ‫ﻓﺎرﻣﺎﮐﻮﻟﻮژي‬ ‫و‬ ‫ﻓﯿﺰﯾﻮﻟﻮژي‬ ‫ﻧﻈﺮ‬‫ي‬
‫آن‬‫ﯾﺎ‬ ‫اﻟﺘﻬﺎب‬ ‫ﻣﺎﻧﻨﺪ‬ ‫ﺳﻠﻮﻟﯽ‬ ‫آﺳﯿﺐ‬ ‫ﺑﻪ‬ ‫ﭘﺎﺳﺦ‬ ‫در‬ ‫دﺧﺎﻟﺖ‬ ‫ﻫﺎ‬
) ‫اﺳﺖ‬ ‫اﯾﺴﮑﻤﯽ‬23-21،‫ﺑﻨﺎﺑﺮاﯾﻦ‬ .(‫اﺳـﺘﺮس‬ ‫ﺑﻪ‬ ‫ﺗﻮﺟﻪ‬ ‫ﺑﺎ‬
‫درﺟـﻪ‬ ‫در‬ ‫آدﻧـﻮزﯾﻦ‬ ‫ﻋﻤﻠﮑـﺮد‬ ‫ﻧﺨﺴﺘﯿﻦ‬ ،‫آﺳﯿﺐ‬ ‫ﯾﺎ‬‫اول‬ ‫ي‬
‫اﯾﺴﮑﻤﯽ‬ ،‫ﻫﺎﯾﭙﻮﮐﺴﯽ‬ ‫ﻃﯽ‬ ‫در‬ ‫ﺑﺎﻓﺘﯽ‬ ‫ﺻﺪﻣﺎت‬ ‫از‬ ‫ﻣﺤﺎﻓﻈﺖ‬
‫ﻣﯽ‬ ‫اﻟﺘﻬﺎب‬ ‫ﯾﺎ‬ ‫و‬) ‫ﺑﺎﺷﺪ‬22‫و‬23،‫ﻣﻮﺿـﻮع‬ ‫اﯾـﻦ‬ ‫ﺗﺄﺋﯿـﺪ‬ ‫در‬ .(
‫ﺗﺤﺮﯾـﮏ‬ ‫ﮐـﻪ‬ ‫داﺷـﺘﻨﺪ‬ ‫اﻇﻬـﺎر‬ ‫ﻫﻤﮑـﺎران‬ ‫و‬ ‫واراﻧﯽ‬
‫ﮔﯿﺮﻧﺪه‬ ‫اﻓﺰاﯾﺸﯽ‬‫ﺑﻪ‬ ‫آدﻧﻮزﯾﻨﯽ‬ ‫ﻫﺎي‬‫وﯾـﮋه‬A2A‫و‬A3
‫ﻓﻌﺎﻟﯿ‬ ‫ﮐﺎﻫﺶ‬ ‫ﺑﺎﻋﺚ‬‫ﻫﺴﺘﻪ‬ ‫ﻋﺎﻣﻞ‬ ‫ﺖ‬‫اي‬) ‫ﮐﺎﭘـﺎﺑﯽ‬NF-
KB‫و‬ (‫ﻃﺮﯾــﻖ‬ ‫از‬ ‫آﻟﻔــﺎ‬ ‫ﺗﻮﻣــﻮري‬ ‫ﻧﮑــﺮوز‬ ‫ﻋﺎﻣــﻞ‬
‫ﻓﻌﺎل‬‫ﻣﻮﻧﻮﻓﺴـﻔﺎت‬ ‫آدﻧﻮزﯾﻦ‬ ‫ﺿﺪاﻟﺘﻬﺎﺑﯽ‬ ‫ﻣﺴﯿﺮ‬ ‫ﺳﺎزي‬
‫ﭘـــﺮوﺗﺌﯿﻦ‬ /‫ﺣﻠﻘـــﻮي‬‫ﮐﯿﻨـــﺎز‬A)cAMP/PKA(
‫ﻣﯽ‬) ‫ﮔﺮدد‬24‫ﺑـﺎ‬ ‫ﺗﻀﺎد‬ ‫در‬ ‫ﮐﻪ‬ ‫اﺳﺖ‬ ‫ﺣﺎﻟﯽ‬ ‫در‬ ‫اﯾﻦ‬ .(
،‫ﯾﺎﻓﺘﻪ‬ ‫اﯾﻦ‬‫ﺑﻪ‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫اوﻫﺘﺎ‬‫ﺗﺄﺛﯿﺮ‬ ‫ﺑﺮرﺳﯽ‬ ‫دﻧﺒﺎل‬
‫ﮐـﺎ‬ ‫ﻣﺨﺘﻠـﻒ‬ ‫ﻣﻘـﺎدﯾﺮ‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬) ‫ﻓﺌﯿﻦ‬10،20‫و‬
100‫ﻣﯿﻠﯽ‬(‫ﺑـﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬ ‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬
‫ﻣﻮش‬ ‫در‬‫ﮐﺮدﻧـﺪ‬ ‫ﺑﯿﺎن‬ ‫ﮐﺒﺪي‬ ‫اﻟﺘﻬﺎب‬ ‫ﺑﻪ‬ ‫ﻣﺒﺘﻼ‬ ‫ﻫﺎي‬
‫ﺑﻠﻮﮐـﻪ‬ ‫ﻃﺮﯾﻖ‬ ‫از‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬
‫ﮔﯿﺮﻧﺪه‬ ‫ﻣﻮﻗﺖ‬ ‫ﮐﺮدن‬‫آدﻧﻮزﯾﻨﯽ‬ ‫ﻫﺎي‬A2A‫ﺑـﻪ‬ ‫ﻣﻨﺠﺮ‬
‫ﭘﺎﺳـــﺦ‬ ‫اﻓـــﺰاﯾﺶ‬ ‫و‬ ‫ﮐﺒـــﺪي‬ ‫آﺳـــﯿﺐ‬ ‫ﺗﺸـــﺪﯾﺪ‬
‫ﺳﯿﺘﻮﮐﯿﻦ‬‫ﻣﯽ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬) ‫ﺷﻮد‬18،‫ﺣـﺎل‬ ‫ﻫﺮ‬ ‫ﺑﻪ‬ .(
ً‫ﻻ‬‫اﺣﺘﻤـﺎ‬ ‫ﺷﺪه‬ ‫ذﮐﺮ‬ ‫ﻣﻄﺎﻟﻌﺎت‬ ‫ﻫﺎي‬ ‫ﯾﺎﻓﺘﻪ‬ ‫ﺑﻪ‬ ‫ﺗﻮﺟﻪ‬ ‫ﺑﺎ‬
‫ﻣﺘﯿـﻞ‬ ‫ﺗﺮﮐﯿﺒﺎت‬ ‫ﺣﺎد‬ ‫ﻣﺼﺮف‬) ‫ﮔﺰاﻧﺘﯿﻨـﯽ‬‫ﻫﻤﭽـﻮن‬
‫ﺑــﻪ‬ ‫ﮐــﺎﻓﺌﯿﻦ‬‫ﻣﻬــﻢ‬ ‫ﻋﻨــﻮان‬‫آﻧﺘﺎﮔﻮﻧﯿﺴــﺖ‬ ‫ﺗــﺮﯾﻦ‬
‫ﮔﯿﺮﻧﺪه‬‫ﺑﺎﻋﺚ‬ ،‫ﻧﮑﺮده‬ ‫ﻋﺎدت‬ ‫اﻓﺮاد‬ ‫در‬ (‫آدﻧﻮزﯾﻨﯽ‬ ‫ﻫﺎي‬
‫ﺑﻪ‬‫و‬‫ﺑﺎﻓـﺖ‬ ‫در‬ ‫اﻟﺘﻬﺎب‬ ‫ﺑﻪ‬ ‫ﺷﺒﯿﻪ‬ ‫ﺣﺎﻟﺘﯽ‬ ‫آﻣﺪن‬ ‫ﺟﻮد‬‫ﻫـﺎ‬
‫ﻣﯽ‬‫ﺷﻮد‬)8‫و‬18(.
‫روﻧـﺪ‬ ‫اداﻣـﻪ‬ ‫در‬ ‫ﺣﺎﺿـﺮ‬ ‫ﺗﺤﻘﯿﻖ‬ ‫ﻧﺘﺎﯾﺞ‬ ،‫ﻫﻤﭽﻨﯿﻦ‬
‫ﺑـﻪ‬ ‫ﭘﺎﯾـﻪ‬ ‫ﺣﺎﻟـﺖ‬ ‫در‬ ‫ﺷـﺪه‬ ‫ﻣﺸﺎﻫﺪه‬ ‫اﻓﺰاﯾﺸﯽ‬ ‫ﭘﺎﺳﺦ‬
‫از‬ ‫ﺣـﺎﮐﯽ‬ ،‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠـﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﻣﺼﺮف‬ ‫دﻧﺒﺎل‬
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﻣﯿﺰان‬ ‫ﻧﺴﺒﯽ‬ ‫ﺗﺸﺪﯾﺪ‬-6‫ﭘـﺲ‬ ‫ﺑﻼﻓﺎﺻﻠﻪ‬
‫واﻣﺎﻧﺪ‬ ‫ﻣﻘﺎوﻣﺘﯽ‬ ‫ﺗﻤﺮﯾﻦ‬ ‫ﺟﻠﺴﻪ‬ ‫ﯾﮏ‬ ‫اﻧﺠﺎم‬ ‫از‬‫ه‬‫در‬ ‫ﺳﺎز‬
‫ﮔﺮوه‬‫ﮐﻨﻨﺪه‬ ‫ﻣﺼﺮف‬ ‫ﻫﺎي‬‫ﺣﺎد‬ ‫ي‬6‫و‬9‫ﮔـﺮم‬ ‫ﻣﯿﻠـﯽ‬
‫ﺑﻪ‬ .‫ﺑﻮد‬ ‫داروﻧﻤﺎ‬ ‫ﮔﺮوه‬ ‫ﺑﺎ‬ ‫ﻣﻘﺎﯾﺴﻪ‬ ‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬‫ﻃﻮري‬‫ﮐﻪ‬
‫ﯾﺎﻓﺘـﻪ‬ ‫ﺑـﺎ‬ ‫ﺗﺤﻘﯿﻖ‬ ‫اﯾﻦ‬ ‫ﻧﺘﺎﯾﺞ‬‫ﻣﻄﺎﻟـﻪ‬ ‫ﻫـﺎي‬‫و‬ ‫ﺗـﻮﻟﺮ‬ ‫ي‬
‫ﻫﻤﮑﺎران‬‫و‬ ‫ﻓﻠﭽﺮ‬ ،‫اﺳـﺖ‬ ‫ﻫﻤﺴﻮ‬ ‫ﻫﻤﮑﺎرن‬ ‫و‬ ‫واﻟﮑﺮا‬
)13،25‫و‬26‫ﺑﻪ‬ .(‫ﺗﺤﻘﯿﻘـﺎﺗﯽ‬ ‫ﮔـﺮوه‬ ،‫ﻣﺜـﺎل‬ ‫ﻋﻨـﻮان‬
‫ﺑﺮرﺳـﯽ‬ ‫ﻣﺘﻌﺎﻗـﺐ‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫ﺗﻮﻟﺮ‬‫ﺣـﺎد‬ ‫ﻣﺼـﺮف‬6
‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺑﺪن‬ ‫وزن‬ ‫در‬ ‫ﮔﺮم‬ ‫ﻣﯿﻠﯽ‬33‫ﻣﺮد‬ ‫دوﻧﺪه‬
‫ﻓﻌﺎﻟﯿﺖ‬ ‫اﻧﺠﺎم‬ ‫و‬15‫داﺷﺘﻨﺪ‬ ‫اﻇﻬﺎر‬ ‫دوﯾﺪن‬ ‫ﮐﯿﻠﻮﻣﺘﺮ‬
‫از‬ ‫ﭘـﺲ‬ ‫ﺳـﺎﻋﺖ‬ ‫دو‬ ‫و‬ ‫ﺑﻼﻓﺎﺻـﻠﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬
‫ﻫﺎي‬ ‫ﺷﺎﺧﺺ‬ ‫ﺑﺮﺧﯽ‬ ‫ﺗﺸﺪﯾﺪ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫ﺑﺪﻧﯽ‬ ‫ﻓﻌﺎﻟﯿﺖ‬
‫ﺧـﻮن‬ ‫ﻫـﺎي‬ ‫ﻟﮑﻮﺳـﯿﺖ‬ ‫)ﺗﻌﺪاد‬ ‫ﺳﯿﺴﺘﻤﯿﮏ‬ ‫اﻟﺘﻬﺎﺑﯽ‬
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ،‫ﻣﺤﯿﻄﯽ‬-10‫و‬6‫ﻣﻘﺎﯾ‬ ‫در‬ (‫ﺳﺮﻣﯽ‬‫ﺴـﻪ‬
‫ﺷﻮد‬ ‫ﻣﯽ‬ ‫داروﻧﻤﺎ‬ ‫ﮔﺮوه‬ ‫ﺑﺎ‬)13(.‫و‬ ‫واﻟﮑـﺮ‬ ،‫ﻫﻤﭽﻨﯿﻦ‬
‫دو‬ ‫ـﯽ‬‫ـ‬‫ﺗﺠﺮﺑ‬ ‫ـﻪ‬‫ـ‬‫ﻧﯿﻤ‬ ‫ـﺮح‬‫ـ‬‫ﻃ‬ ‫ـﮏ‬‫ـ‬‫ﯾ‬ ‫ـﺐ‬‫ـ‬‫ﻗﺎﻟ‬ ‫در‬ ‫ـﺎران‬‫ـ‬‫ﻫﻤﮑ‬
‫ﻣﮑﻤـﻞ‬ ‫ﺣـﺎد‬ ‫ﻣﺼـﺮف‬ ‫ﺑﺮرﺳـﯽ‬ ‫راﺳﺘﺎي‬ ‫در‬ ‫ﮔﺮوﻫﯽ‬
) ‫ﮐﺎﻓﺌﯿﻦ‬6‫ﻣﯿﻠﯽ‬‫وزن‬ ‫از‬ ‫ﮐﯿﻠـﻮﮔﺮم‬ ‫ﻫﺮ‬ ‫ازاي‬ ‫ﺑﻪ‬ ‫ﮔﺮم‬
‫در‬ (‫ﺑﺪن‬12‫دوﭼﺮﺧﻪ‬ ‫ﻣﺮد‬‫از‬ ‫ﭘـﺲ‬ ‫ﺑﻼﻓﺎﺻـﻠﻪ‬ ‫ﺳﻮار‬
‫اﻧﺠﺎم‬90‫دوﭼﺮﺧﻪ‬ ‫دﻗﯿﻘﻪ‬‫ﺑـﺎ‬ ‫ﺗﻌﻘﯿﺒـﯽ‬ ‫ﺳﻮاري‬70%
‫اﮐﺴﯿﮋ‬‫ﻣﺼﺮف‬ ‫ﮐﻪ‬ ‫داﺷﺘﻨﺪ‬ ‫اﺷﺎره‬ ‫ﺑﯿﺸﯿﻨﻪ‬ ‫ﻣﺼﺮﻓﯽ‬ ‫ن‬
‫رﻫـﺎﯾﺶ‬ ‫و‬ ‫ﻟﮑﻮﺳـﯿﺘﻮز‬ ‫اﻓـﺰاﯾﺶ‬ ‫ﺑﺎﻋـﺚ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺣﺎد‬

7. ‫ﺗﺄﺛ‬‫ﯿ‬‫ﺮ‬‫ﺣﺎد‬‫ﺗﻤﺮ‬‫ﯾ‬‫ﻨﺎت‬‫ﻣﻘﺎوﻣﺘ‬‫ﯽ‬‫واﻣﺎﻧﺪه‬‫ﺳﺎز‬‫و‬‫ﻣﺼﺮف‬‫ﻣﻘﺎد‬‫ﯾ‬‫ﺮ‬‫ﻣﺨﺘﻠﻒ‬‫ﮐﺎﻓﺌ‬‫ﯿ‬‫ﻦ‬‫ﺑﺮ‬‫ﭘﺎﺳﺦ‬‫ا‬‫ﯾ‬‫ﻨﺘﺮﻟﻮﮐ‬‫ﯿ‬‫ﻦ‬-6
http://rjms.iums.ac.ir‫ﻋﻠﻮم‬ ‫ﻣﺠﻠﻪ‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394
55
‫ﻫﻮرﻣﻮن‬‫ﻣـﯽ‬ ‫اﺳﺘﺮﺳـﯽ‬ ‫ﻫـﺎي‬) ‫ﮔـﺮدد‬26(.‫اﯾـﻦ‬ ‫در‬
‫ﭘﺎﺳـﺦ‬ ‫ﮐـﻪ‬ ‫ﻣﻌﺘﻘﺪﻧـﺪ‬ ‫ﭘﮋوﻫﺸـﮕﺮان‬ ‫از‬ ‫ﺑﺮﺧﯽ‬ ‫راﺳﺘﺎ‬
‫ﺷـﺎﺧﺺ‬ ‫ﺳﻄﻮح‬ ‫اﻓﺰاﯾﺸﯽ‬‫ﺑـﻪ‬ ‫اﻟﺘﻬـﺎﺑﯽ‬ ‫ﻫـﺎي‬‫دﻧﺒـﺎل‬
‫ـﺎﺛﯿﺮ‬‫ـ‬‫ﺗ‬ ‫از‬ ‫ـﯽ‬‫ـ‬‫ﻧﺎﺷ‬ ً‫ﻻ‬‫ـﺎ‬‫ـ‬‫اﺣﺘﻤ‬ ‫ـﺎﻓﺌﯿﻦ‬‫ـ‬‫ﮐ‬ ‫ـﺎد‬‫ـ‬‫ﺣ‬ ‫ـﺮف‬‫ـ‬‫ﻣﺼ‬
‫ﻫ‬ ‫ﻣﺤﻮر‬ ‫ﺑﺮ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺤﺮك‬‫ﯿﭙﻮﺗﺎﻻﻣﻮس‬-‫ﻫﯿﭙﻮﻓﯿﺰ‬-
) ‫آدرﻧﺎل‬HPA‫ﮐﻪ‬ ‫ﺑﺎﺷﺪ‬ ‫ﻣﺮﮐﺰي‬ ‫ﻋﺼﺒﯽ‬ ‫دﺳﺘﮕﺎه‬ ‫و‬ (
‫ﻫﻮرﻣــﻮن‬ ‫آزادﺳــﺎزي‬ ‫ﺑــﻪ‬ ‫ﻣﻨﺠــﺮ‬‫اﺳﺘﺮﺳــﯽ‬ ‫ﻫــﺎي‬
‫)اﭘــﯽ‬‫و‬ ‫ﻧﻔــﺮﯾﻦ‬‫ﻣــﯽ‬ (‫ﮐــﻮرﺗﯿﺰول‬) ‫ﺷــﻮد‬13،25.(
‫در‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﺣـﺎد‬ ‫ﻣﺼﺮف‬ ‫از‬ ‫ﻧﺎﺷﯽ‬ ‫اﻓﺰاﯾﺶ‬ ،ً‫ﻻ‬‫اﺣﺘﻤﺎ‬
‫ﻫﻮرﻣـﻮن‬ ‫ﻣﻘﺎدﯾﺮ‬‫ﺗﺸـﺪﯾﺪ‬ ‫ﻣﺴـﺌﻮل‬ ‫اﺳﺘﺮﺳـﯽ‬ ‫ﻫـﺎي‬
‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﻓﻌﺎﻟﯿﺖ‬-6‫ﺗﺄﯾﯿـ‬ ‫در‬ .‫ﺑﺎﺷـﺪ‬ ‫ﺑﻮده‬‫اﯾـﻦ‬ ‫ﺪ‬
‫ـﺮ‬‫ـ‬‫ﻓﻠﭽ‬ ‫ـﺎﯾﺞ‬‫ـ‬‫ﻧﺘ‬ ،‫ـﻮع‬‫ـ‬‫ﻣﻮﺿ‬‫ـﺰاﯾﺶ‬‫ـ‬‫اﻓ‬ ‫ـﻪ‬‫ـ‬‫ﺑ‬ ‫ـﺎران‬‫ـ‬‫ﻫﻤﮑ‬ ‫و‬
‫اﭘﯽ‬ ‫ﻏﻠﻈﺖ‬‫ﮔﺮوه‬ ‫در‬ ‫ﻧﻔﺮﯾﻦ‬‫ﮐﻨﻨـﺪه‬ ‫ﻣﺼـﺮف‬ ‫ﻫـﺎي‬‫ي‬
) ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺨﺘﻠﻒ‬ ‫ﻣﻘﺎدﯾﺮ‬ ‫ﺣﺎد‬2‫و‬6‫ﻣﯿﻠﯽ‬‫ﺑـﻪ‬ ‫ﮔﺮم‬
‫اﻓـﺰاﯾﺶ‬ ‫ﺑـﺎ‬ ‫ﻫﻤـﺮاه‬ (‫ﺑﺪن‬ ‫وزن‬ ‫از‬ ‫ﮐﯿﻠﻮﮔﺮم‬ ‫ﻫﺮ‬ ‫ازاي‬
8/1‫و‬2/2‫ـﮕﺮ‬‫ـ‬‫واﮐﻨﺸ‬ ‫ـﺮوﺗﺌﯿﻦ‬‫ـ‬‫ﭘ‬ ‫ـﺮي‬‫ـ‬‫ﺑﺮاﺑ‬-C‫ـﺎره‬‫ـ‬‫اﺷ‬
) ‫دارد‬25‫ﺑــﻪ‬ .(‫ﯾﺎﻓﺘــﻪ‬ ‫اﻓــﺰاﯾﺶ‬ ‫ﺳــﻄﻮح‬ ،‫ﻋــﻼوه‬‫ي‬
‫اﭘﯽ‬‫ﮔﯿﺮﻧﺪه‬ ‫ﺑﺮ‬ ‫ﺗﺄﺛﯿﺮ‬ ‫ﺑﺎ‬ ‫ﻧﯿﺰ‬ ‫ﻧﻔﺮﯾﻦ‬‫ﺑﺘﺎ‬ ‫ﻫﺎي‬-‫آدرﻧﺮژﯾﮏ‬
‫ﺳﻠﻮل‬‫اﯾﻨﺘﺮﻟﻮﮐﯿﻦ‬ ‫ﺳﻨﺘﺰ‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﺎﻋﺚ‬ ‫ﮐﺒﺪي‬ ‫ﻫﺎي‬-
‫ـﻪ‬‫ـ‬‫ﺑ‬ ‫و‬ ‫ـﺶ‬‫ـ‬‫ﺷ‬‫ـﺮوﺗﺌﯿﻦ‬‫ـ‬‫ﭘ‬ ‫ـﺢ‬‫ـ‬‫ﺗﺮﺷ‬ ‫ـﻪ‬‫ـ‬‫ﺑ‬ ‫ـﺮ‬‫ـ‬‫ﻣﻨﺠ‬ ‫ـﺐ‬‫ـ‬‫ﺗﺮﺗﯿ‬
‫واﮐﻨﺸﮕﺮ‬–C‫ﻣﯽ‬ (‫ُﭘﺴﻮﻧﯿﺰاﺳﯿﻮن‬‫ا‬ ‫ﻓﺮآﯾﻨﺪ‬ ‫)ﻃﯽ‬‫ﮔﺮدد‬
)4،5‫ﺑﻪ‬ ‫ﺣﺎل‬ ‫اﯾﻦ‬ ‫ﺑﺎ‬ .(‫ﻣـﯽ‬ ‫ﻧﻈـﺮ‬‫از‬ ‫ﯾﮑـﯽ‬ ‫ﮐـﻪ‬ ‫رﺳـﺪ‬
‫ﻣﺤــﺪودﯾﺖ‬‫ﻋــﺪم‬ ‫ﺣﺎﺿــﺮ‬ ‫ﭘــﮋوﻫﺶ‬ ‫اﺻــﻠﯽ‬ ‫ﻫــﺎي‬
‫ـﺪازه‬‫ـ‬‫اﻧ‬‫ـﺎﮐﻮﻻﻣﯿﻦ‬‫ـ‬‫ﮐﺎﺗ‬ ‫ـﺮات‬‫ـ‬‫ﺗﻐﯿﯿ‬ ‫ـﺰان‬‫ـ‬‫ﻣﯿ‬ ‫ـﺮي‬‫ـ‬‫ﮔﯿ‬‫و‬ ‫ـﺎ‬‫ـ‬‫ﻫ‬
‫ﮐﻮرﺗﯿﮑﻮاﺳﺘﺮوﺋﯿﺪﻫﺎ‬.‫ﺑﺎﺷﺪ‬‫ﺑﺮﺧـﯽ‬ ‫ﻧﺘﺎﯾﺞ‬ ،‫ﻫﻤﭽﻨﯿﻦ‬
‫ﺑـﺎ‬ ‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﻣﮑﻤـﻞ‬ ‫ﮐـﻪ‬ ‫اﺳـﺖ‬ ‫ﺣﺎﮐﯽ‬ ‫ﺗﺤﻘﯿﻘﺎت‬ ‫از‬
‫ﻓﻌﺎﻟﯿ‬ ‫زﻣﺎن‬ ‫ﮐﻤﯽ‬ ‫ﺑﻬﺒﻮد‬‫اﻧﻘﺒﺎض‬ ‫اﻓﺰاﯾﺶ‬ ‫و‬ ‫ﺖ‬‫ﭘﺬﯾﺮي‬
‫ﺷـﺪت‬ ‫ﺗﺤﻤـﻞ‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﺎ‬ ‫اﺳﺖ‬ ‫ﻣﻤﮑﻦ‬‫ﺑـﺎﻻي‬ ‫ﻫـﺎي‬
‫ﻣﮑـﺎﻧﯿﮑﯽ‬ ‫ﻓﺸﺎر‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﺎﻋﺚ‬ ،‫ﺗﻤﺮﯾﻦ‬-‫ﻣﺘـﺎﺑﻮﻟﯿﮑﯽ‬
‫ﺗﺸـﺪﯾﺪ‬ ‫ﺑـﻪ‬ ‫ﻣﻨﺠـﺮ‬ ‫و‬ ‫ﺷـﺪه‬ ‫ﺳـﺎرﮐﻮﻟﻤﺎ‬ ‫ﺑﺮ‬ ‫ﺑﯿﺸﺘﺮي‬
) ‫ﺷﻮد‬ ‫ﺳﻠﻮﻟﯽ‬ ‫آﺳﯿﺐ‬27‫ﮐـﻪ‬ ‫اﺳـﺖ‬ ‫ﺣﺎﻟﯽ‬ ‫در‬ ‫اﯾﻦ‬ .(
‫ـﻪ‬‫ـ‬‫ﻣﻄﺎﻟﻌ‬ ‫در‬‫ـﯽ‬‫ـ‬‫ﻣﻌﻨ‬ ‫ـﺎوت‬‫ـ‬‫ﺗﻔ‬ ‫ـﯿﭻ‬‫ـ‬‫ﻫ‬ ‫ـﺮ‬‫ـ‬‫ﺣﺎﺿ‬ ‫ي‬‫از‬ ‫داري‬
‫ﮔﺮ‬ ‫ﻣﯿﺎن‬ ‫ﺷﺪه‬ ‫اﻧﺠﺎم‬ ‫ﮐﺎر‬ ‫ﻣﯿﺰان‬ ‫ﻟﺤﺎظ‬‫وه‬‫ﻣﺸﺎﻫﺪه‬ ‫ﻫﺎ‬
.‫ﻧﮕﺮدﯾﺪ‬
‫ﯾﺎﻓﺘﻪ‬ ،‫ﻃﺮﻓﯽ‬ ‫از‬‫ﻣﻄﺎﻟﻌـﺎت‬ ‫ﻧﺘـﺎﯾﺞ‬ ‫ﺑﺎ‬ ‫ﺗﺤﻘﯿﻖ‬ ‫ي‬ ‫ﻫﺎ‬
‫در‬ ‫ﻫﻤﮑـﺎران‬ ‫و‬ ‫ﺟﻌﻔـﺮي‬ ‫و‬ ‫ﻫﻤﮑـﺎران‬ ‫و‬ ‫ﻫﺎرﯾﮕﺎن‬
‫اﺳـﺖ‬ ‫ﺗﻀﺎد‬)28‫و‬29(‫و‬ ‫ﺟﻌﻔـﺮي‬ ،‫راﺳـﺘﺎ‬ ‫اﯾـﻦ‬ ‫در‬ .
‫ﺑﻪ‬ ‫ﻫﻤﮑﺎران‬‫ﻣﮑﻤﻞ‬ ‫دﻧﺒﺎل‬‫ﺳﺎزي‬14‫روزه‬‫ي‬5‫ﻣﯿﻠﯽ‬
‫ﻓﻌـﺎل‬ ‫ﻣـﺮدان‬ ‫در‬ ‫روز‬ ‫در‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﺑﺪن‬ ‫وزن‬ ‫در‬ ‫ﮔﺮم‬
‫اﻧﺠﺎم‬ ‫ﻣﺘﻌﺎﻗﺐ‬30‫دو‬ ‫دﻗﯿﻘﻪ‬‫ﺑﺎ‬ ‫ﻧﻮارﮔﺮدان‬ ‫روي‬ ‫ﯾﺪن‬
‫ﻣﮑﻤﻞ‬ ،‫داﺷﺘﻨﺪ‬ ‫اﻇﻬﺎر‬ ‫ﻣﻨﻔﯽ‬ ‫ﺷﯿﺐ‬‫ﮐـﺎﻓﺌﯿﻦ‬ ‫ﺳـﺎزي‬
‫ﺑﻪ‬‫ﻣﻌﻨـﯽ‬ ‫ﻃﻮر‬‫اﻟﺘﻬـﺎﺑﯽ‬ ‫ﻋﻼﺋـﻢ‬ ‫اﻓـﺰاﯾﺶ‬ ‫از‬ ‫داري‬24
‫ﻣـﯽ‬ ‫ﺟﻠﻮﮔﯿﺮي‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫از‬ ‫ﭘﺲ‬ ‫ﺳﺎﻋﺖ‬) ‫ﻧﻤﺎﯾـﺪ‬29.(
‫داﺷـﺘﻨﺪ‬ ‫اﻇﻬـﺎر‬ ‫ﻧﯿﺰ‬ ‫ﻫﻤﮑﺎران‬ ‫و‬ ‫ﻫﺎرﯾﮕﺎن‬ ،‫ﻋﻼوه‬ ‫ﺑﻪ‬
‫ﻣﺼﺮف‬ ‫ﮐﻪ‬600‫ﻣﯿﻠﯽ‬‫ﺑﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫روز‬ ‫در‬ ‫ﮔﺮم‬‫ﻣـﺪت‬
‫ﭘﺎﺳـﺦ‬ ‫ﺗﻌـﺪﯾﻞ‬ ‫ﺑﺎﻋﺚ‬ ‫ﻫﻔﺘﻪ‬ ‫ﯾﮏ‬‫ﭘـﺮوﺗﺌﯿﻦ‬ ‫اﻟﺘﻬـﺎﺑﯽ‬
‫واﮐﻨﺸﮕﺮ‬-C‫ﻣﯽ‬ ‫ﺳﺎﻟﻢ‬ ‫ﻣﺮدان‬ ‫در‬) ‫ﺷﻮد‬28‫اﯾـﻦ‬ ‫ﺑﺎ‬ .(
‫ﻣﻄﺎﻟﻌـﺎت‬ ‫ﺑـﺎ‬ ‫ﺣﺎﺿﺮ‬ ‫ﺗﺤﻘﯿﻖ‬ ‫ﻧﺘﺎﯾﺞ‬ ‫در‬ ‫ﺗﻔﺎوت‬ ،‫ﺣﺎل‬
‫ﻣﯽ‬ ً‫ﻻ‬‫اﺣﺘﻤﺎ‬ ‫ﺷﺪه‬ ‫ذﮐﺮ‬‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻗﺮارداد‬ ‫از‬ ‫ﻧﺎﺷﯽ‬ ‫ﺗﻮاﻧﺪ‬
‫و‬ ‫ـﯽ‬‫ـ‬‫واراﻧ‬ ،‫ـﯿﻪ‬‫ـ‬‫ﻓﺮﺿ‬ ‫ـﻦ‬‫ـ‬‫اﯾ‬ ‫ـﺪ‬‫ـ‬‫ﺗﺄﺋﯿ‬ ‫در‬ .‫ـﺪ‬‫ـ‬‫ﺑﺎﺷ‬ ‫ـﺮﻓﯽ‬‫ـ‬‫ﻣﺼ‬
‫ﻣﻄﺎﻟﻌـﻪ‬ ‫ﺑﺎ‬ ‫ﻫﻤﮑﺎران‬‫ي‬33‫دﻧﺒـﺎل‬ ‫ﺑـﻪ‬ ‫ﺳـﺎﻟﻢ‬ ‫ﻣـﺮد‬
) ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺰﻣﻦ‬ ‫ﻣﺼﺮف‬400‫و‬600‫ﻣﯿﻠﯽ‬‫ﺑـﻪ‬ ‫ﮔـﺮم‬
‫ﺗﻤـﺎﻣﯽ‬ ‫ﻣﺼـﺮف‬ ‫ﮐﻪ‬ ‫داﺷﺘﻨﺪ‬ ‫اﻇﻬﺎر‬ (‫ﻫﻔﺘﻪ‬ ‫دو‬ ‫ﻣﺪت‬
‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﻘﺎدﯾﺮ‬12،24‫و‬36‫ﻗﻄـﻊ‬ ‫از‬ ‫ﭘﺲ‬ ‫ﺳﺎﻋﺖ‬
‫ﮔﯿﺮﻧﺪه‬ ‫اﺗﺼﺎل‬ ‫ﻣﯿﺰان‬ ‫اﻓﺰاﯾﺶ‬ ‫ﺑﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫ﻣﺼﺮف‬‫ﻫﺎي‬
‫آدﻧﻮزﯾﻨﯽ‬A2A‫ﻧﻮﺗﺮوﻓﯿﻞ‬ ‫در‬‫ﺷـﺎﺧﺺ‬ ‫ﺗﻌـﺪﯾﻞ‬ ‫و‬ ‫ﻫـﺎ‬
) ‫ﮔﺮدﯾﺪ‬ ‫اﮐﺴﺎﯾﺸﯽ‬ ‫و‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﻫﺎي‬30‫ﺑﻪ‬ .(‫ﻃﻮري‬‫ﮐﻪ‬
‫ﺑﯿـﺎن‬ ‫اﻓـﺰاﯾﺶ‬ ‫ﺑـﻪ‬ ‫ﻣﻨﺠﺮ‬ ‫ﺧﻮد‬ ‫ﻋﻤﻞ‬ ‫اﯾﻦ‬ ‫ﺑﺎ‬ ‫ﮐﺎﻓﺌﯿﻦ‬
‫ﮔﯿﺮﻧﺪه‬ ‫اﻧﺘﻘﺎل‬ ،‫ﻣﺜﺒﺖ‬‫و‬ ‫ﺳـﻠﻮل‬ ‫ﻏﺸـﺎء‬ ‫ﺳـﻄﺢ‬ ‫ﺑﻪ‬ ‫ﻫﺎ‬
‫ـﺪه‬‫ـ‬‫ﮔﯿﺮﻧـ‬ ‫ـﯿﺖ‬‫ـ‬‫ﺣﺴﺎﺳـ‬ ‫ـﺰاﯾﺶ‬‫ـ‬‫اﻓـ‬‫ـﻮزﯾﻨﯽ‬‫ـ‬‫آدﻧـ‬ ‫ـﺎي‬‫ـ‬‫ﻫـ‬
‫ـﻪ‬‫ـ‬‫ﺑ‬‫ﺧﺼــﻮص‬A2A‫و‬A3‫ـﯽ‬‫ـ‬‫ﻣ‬) ‫ﺷــﻮد‬8،23‫و‬24.(
‫ﮔﯿﺮﻧﺪه‬ ‫اﯾﻦ‬ ‫ﻓﻌﺎﻟﯿﺖ‬ ‫اﻓﺰاﯾﺶ‬‫ﺑـﻪ‬ ‫ﻧﯿـﺰ‬ ‫آدﻧﻮزﯾﻨﯽ‬ ‫ﻫﺎي‬
‫ـﻪ‬‫ـ‬‫ﻧﻮﺑ‬‫ـﺰﯾﻢ‬‫ـ‬‫آﻧ‬ ‫ـﺖ‬‫ـ‬‫ﻓﻌﺎﻟﯿ‬ ‫ـﺰاﯾﺶ‬‫ـ‬‫اﻓ‬ ‫ـﻪ‬‫ـ‬‫ﺑ‬ ‫ـﺮ‬‫ـ‬‫ﻣﻨﺠ‬ ‫ـﻮد‬‫ـ‬‫ﺧ‬ ‫ي‬
‫ـﯿﮑﻼ‬‫ـ‬‫ﺳ‬ ‫ـﯿﻼت‬‫ـ‬‫آدﻧ‬‫ـﺪاﻟﺘﻬﺎﺑﯽ‬‫ـ‬‫ﻣﺴﯿﺮﺿ‬ ‫ـﮏ‬‫ـ‬‫ﺗﺤﺮﯾ‬ ‫و‬ ‫ز‬
PKA/cAMP‫ﺑﺎﻋﺚ‬ ‫و‬ ‫ﺷﺪه‬،‫ﮐﯿﻤﻮﺗﺎﮐﺴـﯽ‬ ‫ﮐﺎﻫﺶ‬
‫ﺳـﻠﻮل‬ ‫اﻧـﻮاع‬ ‫ﻓﻌﺎﻟﯿـﺖ‬ ‫و‬ ‫ﭼﺴﺒﻨﺪﮔﯽ‬ ،‫ﺣﺮﮐﺖ‬‫ﻫـﺎي‬
‫ﺳـﻠﻮل‬ ‫ﺷﺎﻣﻞ‬ ‫ﮔﻮﻧﺎﮔﻮن‬ ‫اﻟﺘﻬﺎﺑﯽ‬‫ﻫـﺎي‬T‫ﮐﺸـﻨﺪه‬‫ي‬
‫ﻟﻨﻔﻮﺳـﯿﺖ‬ ،‫ﻃﺒﯿﻌﯽ‬‫ﻧﻮﺗﺮوﻓﯿـﻞ‬ ‫و‬ ‫ﻫـﺎ‬‫ﻣـﯽ‬ ‫ﻫـﺎ‬‫ﮔـﺮدد‬
)30‫و‬31.(
‫ﻣﻄﺎﻟﻌﻪ‬ ‫ﻧﺘﺎﯾﺞ‬‫ﻧﮑﺘﻪ‬ ‫اﯾﻦ‬ ‫ﺑﺮ‬ ‫اﺳﺖ‬ ‫ﺗﺄﯾﯿﺪي‬ ‫ﺣﺎﺿﺮ‬ ‫ي‬
‫ﺷﮑﻞ‬ ‫ﺑﻪ‬ ‫ﮐﺎﻓﺌﯿﻦ‬ ‫ﻣﺼﺮف‬ ‫ﮐﻪ‬‫ﺑـﺮوز‬ ‫ﺑﺎﻋﺚ‬ ‫ﺣﺎد‬‫ﯾـﮏ‬
‫داﻣﻨـﻪ‬ ‫در‬ ‫و‬ ‫ﭘﺎﯾﯿﻦ‬ ‫ﺳﻄﺢ‬ ‫اﻟﺘﻬﺎﺑﯽ‬ ‫ﭘﺎﺳﺦ‬‫ﻃﺒﯿﻌـﯽ‬ ‫ي‬
‫ﺳﺎﻟﻢ‬ ‫اﻓﺮاد‬ ‫ﺑﻪ‬ ‫ﻣﺮﺑﻮط‬-. ‫ﮔﺮدد‬ ‫ﻣﯽ‬‫ﭼﻨﺪ‬ ‫ﻫﺮ‬‫ﺑﺎﺗﻮﺟﻪ‬
‫ﯾﺎﻓﺘـﻪ‬ ‫ﺑﻪ‬ ‫ﻣﺮﺑﻮط‬ ‫ﺗﻀﺎدﻫﺎي‬ ‫ﺑﺮﺧﯽ‬ ‫ﺑﻪ‬‫و‬ ‫ﻗﺒﻠـﯽ‬ ‫ﻫـﺎي‬
‫ﻣﺤﺪودﯾﺖ‬‫اﻧـﺪازﮔﯿﺮي‬ ‫)ﻋـﺪم‬ ‫ﺣﺎﺿـﺮ‬ ‫ﺗﺤﻘﯿـﻖ‬ ‫ﻫﺎي‬
‫ﮔﯿﺮﻧﺪه‬ ‫ﻣﯿﺰان‬‫ﻫـﺎي‬ ‫ﻫﻮرﻣﻮن‬ ‫ﺳﻄﺢ‬ ،‫آدﻧﻮزﯾﻨﯽ‬ ‫ﻫﺎي‬
‫ﺷـــﺎﺧﺺ‬ ‫ﺳـــﺎﯾﺮ‬ ‫و‬ ‫ـﯽ‬‫ـ‬‫اﺳﺘﺮﺳـ‬‫اﻟﺘﻬـــﺎﺑ‬ ‫ﻫـــﺎي‬‫و‬ ‫ﯽ‬
‫ﻣﯽ‬ (‫ﺿﺪاﻟﺘﻬﺎﺑﯽ‬‫ﺑـﺮاي‬ ‫ﻫﻨـﻮز‬ ‫ﮐﻪ‬ ‫داﺷﺖ‬ ‫اذﻋﺎن‬ ‫ﺗﻮان‬
‫ﻧﺘﯿﺠﻪ‬ ‫ﺑﻪ‬ ‫دﺳﺘﯿﺎﺑﯽ‬‫ﺑﯿﺸﺘﺮي‬ ‫ﻣﻄﺎﻟﻌﺎت‬ ،‫ﻗﻄﻌﯽ‬ ‫ﮔﯿﺮي‬
.‫دارد‬ ‫ﺿﺮورت‬

8. ‫راﻣ‬‫ﯿ‬‫ﻦ‬‫اﻣ‬‫ﯿ‬‫ﺮﺳﺎﺳﺎن‬‫ﻫﻤﮑﺎر‬ ‫و‬‫ان‬
‫ﻣﺠﻠﻪ‬‫ﻋﻠﻮم‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394http://rjms.iums.ac.ir
56
‫ﺗﺸﮑﺮ‬ ‫و‬ ‫ﺗﻘﺪﯾﺮ‬
‫ـﻮدﻧﯽ‬‫ـ‬‫آزﻣ‬ ‫از‬ ‫ـﻨﺪﮔﺎن‬‫ـ‬‫ﻧﻮﯾﺴ‬‫ـﻪ‬‫ـ‬‫ﮐ‬ ‫ـﺎﻧﯽ‬‫ـ‬‫ﮐﺴ‬ ‫ـﻪ‬‫ـ‬‫ﮐﻠﯿ‬ ‫و‬ ‫ـﺎ‬‫ـ‬‫ﻫ‬
‫ﻫﻤﮑــﺎري‬‫ﺣﺎﺿــﺮ‬ ‫ﭘــﮋوﻫﺶ‬ ‫اﺟــﺮاي‬ ‫در‬ ‫را‬ ‫ﻻزم‬ ‫ﻫــﺎي‬
.‫دارﻧﺪ‬ ‫را‬ ‫ﻗﺪرداﻧﯽ‬ ‫و‬ ‫ﺗﺸﮑﺮ‬ ‫ﮐﻤﺎل‬ ‫داﺷﺘﻨﺪ‬
‫ﻣﻨﺎﺑﻊ‬
1. Buford TW, Cooke MB, Willoughby DS.
Resistance exercise-induced changes of
inflammatory gene expression within human
skeletal muscle. Eur J Appl Physiol 2009;107 (4):
463-471.
2. Uchida MC, Nosaka K, Ugrinowitsch C,
Yamashita A, Martins EJr, Moriscot AS, et al.
Effect of bench press exercise intensity on muscle
soreness and inflammatory mediators. J Sports Sci
2009;27(5):499-507.
3. Libardi CA, De Souza GV, Cavaglieri CR,
Madruga VA, Chacon-Mikahil MP. Effect of
resistance, endurance and concurrent training on
TNFα, IL-6 and CRP. Med Sci Sports Exerc
2012;44(1):50-63.
4. Fatouros I, Chatzinikolaou A, Paltoglou G,
Petridou A, Avloniti A, Jamurtas A, et al. Acute
resistance exercise results in catecholaminergic
rather than hypothalamic-pituitary-adrenal axis
stimulation during exercise in young men. Stress
2010;13(6):461-468.
5. Barquilha G, Uchida M, Santos V, Moura N,
Lambertucci R, Hatanaka E, et al. Characterization
of the effects of one maximal repetition test on
muscle injury and inflammation markers. Web
Medcentral Physiol 2011;2(3):1-8.
6. Jordan SL. The effects of green tea extract
supplementation on delayed onset muscle soreness
and oxidative stress. Texas Tech University 2007.
7. Heckman MA, Weil J, Gonzalez de Mejia E.
Caffeine (1, 3, 7-trimethylxanthine) in foods: a
comprehensive review on consumption,
functionality, safety, and regulatory matters. J Food
Sci 2010; 75(3):77-87.
8. Hasko G, Cronstein B. Methylxanthines and
inflammatory cells. Methylxanthines 2011;200:
457-68.
9. Hasko G, Linden J, Cronstein B, Pacher P.
Adenosine receptors: therapeutic aspects for
inflammatory and immune diseases. Nat Rev Drug
Discov 2008;7(9):759-770.
10. Chavez Valdez R, Ahlawat R, Nathan A,
Wills-Karp M, Sproles A, Gauda EB. Distinct
Mechanisms Mediate the Concentration-dependent
modulation of Caffeine on TNF- and IL-10
Production By Cord Blood Mononuclear Cells
(CBM). Am J Res Critic Care Med 2009;181:5726-
32.
11. Dray C, Guigné C, Valet P, Castan-Laurell I.
Caffeine reduces TNFalpha up-regulation in human
adipose tissue primary culture. J Physiol Biochem
2007;63(4):329-336.
12. Machado M, Koch AJ, Willardson JM, dos
Santos FC, Curty VM, Pereira LN. Caffeine does
not augment markers of muscle damage or
leukocytosis following resistance exercise. Int J
Sports Physiol Perform 2010;5(1):18-26.
13. Tauler P, Martínez S, Moreno C, Monjo M,
Martínez P, Aguiló A. Effects of caffeine on the
inflammatory response induced by a 15-km run
competition. Med Sci Sports Exerc
2013;45(7):1269-1276.
14. Gibson RS. Principles of Nutritional
Assessment. USA: Oxford University Press; 2005.
15. Gordon NF. ACSM's guidelines for exercise
testing and prescription. USA: Lippincott Williams
& Wilkins; 2009.
16. Graham TE. Caffeine and exercise:
metabolism, endurance and performance. Sports
Med 2001; 31(11):785-807.
17. Wedick NM, Brennan AM, Sun Q, Hu FB,
Mantzoros CS, Van Dam RM. Effects of
caffeinated and decaffeinated coffee on biological
risk factors for type 2 diabetes: a randomized
controlled trial. Nutr J 2011;13:1475-2891.
18. Ohta A, Lukashev D, Jackson EK, Fredholm
BB, Sitkovsky M. 1,3,7-trimethylxanthine
(Caffeine) may exacerbate acute inflammatory
liver injury by weakening the physiological
immunosuppressive mechanism. J Immunol
2007;179(11);7431-7438.
19. Kempf K, Herder C, Erlund I, Kolb H,
Martin S, Carstensen M, et al. Effects of coffee
consumption on subclinical inflammation and other
risk factors for type 2 diabetes: a clinical trial. Am
J Clin Nutr 2010;91(4):950-957.
20. Arsenault BJ, Earnest CP, Després JP, Blair
SN, Church TS. Obesity, coffee consumption and
CRP levels in postmenopausal overweight/obese
women: importance of hormone replacement
therapy use. Eur J Clin Nutr 2009;63(12):1419-
1424.
21. Fredholm BB. Caffeine and the biological
role of adenosine receptors. J Alzheimers Dis
2009;4 (6):15-31.
22. Fredholm BB. Adenosine, an endogenous
distress signal, modulates tissue damage and repair.
Cell Death Differ 2007;14:(7):1315-1323.
23. Morello S, Sorrentino R, Pinto A. Adenosine
A2a receptor agonists as regulators of
inflammation: pharmacology and therapeutic
opportunities. J Rec Ligand Channel Res
2009;2:11-7.
24. Varani K, Vincenzi F, Tosi A, Gessi S,
Casetta I, Granieri G, et al. A2A adenosine
receptor overexpression and functionality, as well
as TNF-α levels, correlate with motor symptoms in

9. ‫ﺗﺄﺛ‬‫ﯿ‬‫ﺮ‬‫ﺣﺎد‬‫ﺗﻤﺮ‬‫ﯾ‬‫ﻨﺎت‬‫ﻣﻘﺎوﻣﺘ‬‫ﯽ‬‫واﻣﺎﻧﺪه‬‫ﺳﺎز‬‫و‬‫ﻣﺼﺮف‬‫ﻣﻘﺎد‬‫ﯾ‬‫ﺮ‬‫ﻣﺨﺘﻠﻒ‬‫ﮐﺎﻓﺌ‬‫ﯿ‬‫ﻦ‬‫ﺑﺮ‬‫ﭘﺎﺳﺦ‬‫ا‬‫ﯾ‬‫ﻨﺘﺮﻟﻮﮐ‬‫ﯿ‬‫ﻦ‬-6
http://rjms.iums.ac.ir‫ﻋﻠﻮم‬ ‫ﻣﺠﻠﻪ‬‫رازي‬ ‫ﭘﺰﺷﮑﯽ‬‫دوره‬22‫ﺷﻤﺎره‬ ،134،‫ﻣ‬‫ﺮ‬‫داد‬1394
57
Parkinson’s disease. FASEB J 2010;24(2):587-598.
25. Fletcher DK, Bishop NC. Effect of a single
and repeated dose of caffeine on antigen-stimulated
human natural killer cell CD69 expression after
high-intensity intermittent exercise. Eur J Appl
Physiol 2011;111(7):1329-1339.
26. Walker GJ, Dziubak A, Houghton L,
Prendergast C, Lim L, Bishop NC. The effect of
caffeine ingestion on human neutrophil oxidative
burst responses following time-trial cycling. J
Sports Sci 2008;26(6):611-619.
27. Bassini-Cameron A, Sweet E, Bottino A,
Bittar C, Veiga C, Cameron LC. Effect of caffeine
supplementation on haematological and
biochemical variables in elite soccer players under
physical stress conditions. Br J Sports Med
2007;41(8):523-30.
28. Horrigan LA, Kelly JP, Connor TJ. Caffeine
suppresses TNF-alpha production via activation of
the cyclic AMP/protein kinase A pathway. Int
Immunopharmacol 2004;4(10-11):1409-1417.
29. Jafari A, Nik-kherad J, Malekirad AA. Effect
of short-term caffeine supplementation on downhill
running- induced inflammatory response in non-
athletes males. J Cell Tissue 2012;2:377-85.
[Persian].
30. Varani K, Portaluppi F, Gessi S, Merighi S,
Vincenzi F, Cattabriga E, et al. Caffeine intake
induces an alteration in human neutrophil A2A
adenosine receptors. Cell Mol Life Sci 2005;62(19-
20):2350-238.
31.Chouker A, Thiel M, Lukashev D, Ward JM,
Kaufmann I, Apasov S, et al. Critical role of
hypoxia and A2A adenosine receptors in liver
tissue-protecting physiological anti-inflammatory
pathway. Mol Med 2008;14(2):116-123.

10. Original Article http://rjms.iums.ac.ir
Razi Journal of Medical Sciences Vol. 22, No. 134, July-Aug 2015 58
The acute effects of exhaustive resistance training and different dosages of
caffeine intake on IL-6 response
Ramin Amirsasan, Associate Professor of Exercise Physiology and Sport Nutrition, faculty of
University of Tabriz, Tabriz, Iran. amirsasan@tabrizu.ac.ir
Mir-Majid Khaleghi-Anbardan, MSc in Exercise and Sport Physiology, faculty of University of
Tabriz, Tabriz, Iran. arashkhaleghi68@yahoo.com
*Ali Zarghami Khameneh, PhD student of Exercise & Sport Physiology; faculty of Physical
Education, University of Tabriz, Tabriz, Iran (*Corresponding author). ali.zarghami64@gmail.com
Abstract
Background: Based on the limited and inconsistent results about the effects of acute
methylxanthine component on exercise-induced inflammatory response, the present study
was conducted to identify the effect of acute different doses of caffeine intake on serum
interleukin-6 (IL-6) response in male volleyball players following one-session of exhaustive
resistance exercise.
Methods: Thirty male volleyball players (aged 21.47±1.45 years, fat 10.47±3.11%, and BMI
23.15±1.26 kg.m2) in a quasi-experimental, randomized and double-blind design were
allocated equally into three randomized groups: supplement groups (Caffeine intake: 6 or 9
mg.kg-1) and placebo group (Dextrose intake: 6 mg.kg-1). About 45 min after the
supplementation subjects were participated in a one-session resistance weight-exercise (7
stations in 3 sets per station with 80% of one repetition maximum until exhaustive). Changes
in inflammatory index (serum IL-6) were determined in three phases (baseline, 45 min after
the supplementation (before exercise) and immediately post-exercise protocol).The normal
data were analyzed by repeated measure ANOVA and Bonferroni at α≤0.05.
Results: The results show that the acute ingested caffeine doses of 6 and 9 mg-1 has
significant effect (p≤0.05) on the basal changes in serum IL-6. Moreover, both ingested
caffeine dosages of 6 and 9 mg-1 in interaction with the resistance exercise worsened the
inflammatory indices as compared to placebo group (p≤0.05).
Conclusion: Based on the present results, it can be concluded that acute different doses of
caffeine intake at baseline induces low grade inflammation (increase in the serum IL-6) and
also cannot decrease the undesirable inflammatory indices response induced by one-session
of resistance exercise in male volleyball players.
Keywords: Interleukin-6, Caffeine, Acute resistance training